1
|
Bheri S, Brown ME, Park HJ, Brazhkina O, Takaesu F, Davis ME. Customized Loading of microRNA-126 to Small Extracellular Vesicle-Derived Vehicles Improves Cardiac Function after Myocardial Infarction. ACS Nano 2023; 17:19613-19624. [PMID: 37715735 PMCID: PMC10604069 DOI: 10.1021/acsnano.3c01534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Accepted: 09/01/2023] [Indexed: 09/18/2023]
Abstract
Small extracellular vesicles (sEVs) are promising for cell-based cardiac repair after myocardial infarction. These sEVs encapsulate potent cargo, including microRNAs (miRs), within a bilayer membrane that aids sEV uptake when administered to cells. However, despite their efficacy, sEV therapies are limited by inconsistencies in the sEV release from parent cells and variability in cargo encapsulation. Synthetic sEV mimics with artificial bilayer membranes allow for cargo control but suffer poor stability and rapid clearance when administered in vivo. Here, we developed an sEV-like vehicle (ELV) using an electroporation technique, building upon our previously published work, and investigated the potency of delivering electroporated ELVs with pro-angiogenic miR-126 both in vitro and in vivo to a rat model of ischemia-reperfusion. We show that electroporated miR-126+ ELVs improve tube formation parameters when administered to 2D cultures of cardiac endothelial cells and improve both echocardiographic and histological parameters when delivered to a rat left ventricle after ischemia reperfusion injury. This work emphasizes the value of using electroporated ELVs as vehicles for delivery of select miR cargo for cardiac repair.
Collapse
Affiliation(s)
- Sruti Bheri
- Wallace
H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
| | - Milton E. Brown
- Wallace
H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
| | - Hyun-Ji Park
- Wallace
H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
- Department
of Molecular Science and Technology, Ajou
University, Suwon 16499, Korea
| | - Olga Brazhkina
- Wallace
H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
| | - Felipe Takaesu
- Wallace
H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
- Biochemistry,
Cell and Developmental Biology Graduate Training Program, Graduate
Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, Georgia 30332, United States
| | - Michael E. Davis
- Wallace
H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
- Children’s
Heart Research and Outcomes (HeRO) Center, Children’s Healthcare of Atlanta and Emory University, Atlanta, Georgia 30322, United States
| |
Collapse
|
2
|
Ohanele C, Peoples JN, Karlstaedt A, Geiger JT, Gayle AD, Ghazal N, Sohani F, Brown ME, Davis ME, Porter GA, Faundez V, Kwong JQ. Mitochondrial citrate carrier SLC25A1 is a dosage-dependent regulator of metabolic reprogramming and morphogenesis in the developing heart. bioRxiv 2023:2023.05.22.541833. [PMID: 37292906 PMCID: PMC10245819 DOI: 10.1101/2023.05.22.541833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The developing mammalian heart undergoes an important metabolic shift from glycolysis toward mitochondrial oxidation, such that oxidative phosphorylation defects may present with cardiac abnormalities. Here, we describe a new mechanistic link between mitochondria and cardiac morphogenesis, uncovered by studying mice with systemic loss of the mitochondrial citrate carrier SLC25A1. Slc25a1 null embryos displayed impaired growth, cardiac malformations, and aberrant mitochondrial function. Importantly, Slc25a1 haploinsufficient embryos, which are overtly indistinguishable from wild type, exhibited an increased frequency of these defects, suggesting Slc25a1 dose-dependent effects. Supporting clinical relevance, we found a near-significant association between ultrarare human pathogenic SLC25A1 variants and pediatric congenital heart disease. Mechanistically, SLC25A1 may link mitochondria to transcriptional regulation of metabolism through epigenetic control of PPARγ to promote metabolic remodeling in the developing heart. Collectively, this work positions SLC25A1 as a novel mitochondrial regulator of ventricular morphogenesis and cardiac metabolic maturation and suggests a role in congenital heart disease.
Collapse
|
3
|
Park HJ, Hoffman JR, Brown ME, Bheri S, Brazhkina O, Son YH, Davis ME. Knockdown of deleterious miRNA in progenitor cell-derived small extracellular vesicles enhances tissue repair in myocardial infarction. Sci Adv 2023; 9:eabo4616. [PMID: 36867699 PMCID: PMC9984177 DOI: 10.1126/sciadv.abo4616] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Accepted: 01/31/2023] [Indexed: 06/18/2023]
Abstract
Small extracellular vesicles (sEVs) play a critical role in cardiac cell therapy by delivering molecular cargo and mediating cellular signaling. Among sEV cargo molecule types, microRNA (miRNA) is particularly potent and highly heterogeneous. However, not all miRNAs in sEV are beneficial. Two previous studies using computational modeling identified miR-192-5p and miR-432-5p as potentially deleterious in cardiac function and repair. Here, we show that knocking down miR-192-5p and miR-432-5p in cardiac c-kit+ cell (CPC)-derived sEVs enhances the therapeutic capabilities of sEVs in vitro and in a rat in vivo model of cardiac ischemia reperfusion. miR-192-5p- and miR-432-5p-depleted CPC-sEVs enhance cardiac function by reducing fibrosis and necrotic inflammatory responses. miR-192-5p-depleted CPC-sEVs also enhance mesenchymal stromal cell-like cell mobilization. Knocking down deleterious miRNAs from sEV could be a promising therapeutic strategy for treatment of chronic myocardial infarction.
Collapse
Affiliation(s)
- Hyun-Ji Park
- Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA 30322, USA
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea
| | - Jessica R. Hoffman
- Molecular and Systems Pharmacology Graduate Training Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA 30322, USA
| | - Milton E. Brown
- Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA 30322, USA
| | - Sruti Bheri
- Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA 30322, USA
| | - Olga Brazhkina
- Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA 30322, USA
| | - Young Hoon Son
- Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA 30322, USA
| | - Michael E. Davis
- Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA 30322, USA
- Molecular and Systems Pharmacology Graduate Training Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA 30322, USA
- Children's Heart Research and Outcomes (HeRO) Center, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
| |
Collapse
|
4
|
Streeter BW, Brown ME, Shakya P, Park HJ, Qiu J, Xia Y, Davis ME. Using computational methods to design patient-specific electrospun cardiac patches for pediatric heart failure. Biomaterials 2022; 283:121421. [DOI: 10.1016/j.biomaterials.2022.121421] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 01/12/2022] [Accepted: 02/17/2022] [Indexed: 12/15/2022]
|
5
|
Bejleri D, Robeson MJ, Brown ME, Hunter J, Maxwell JT, Streeter BW, Brazhkina O, Park HJ, Christman KL, Davis ME. In vivo evaluation of bioprinted cardiac patches composed of cardiac-specific extracellular matrix and progenitor cells in a model of pediatric heart failure. Biomater Sci 2022; 10:444-456. [PMID: 34878443 PMCID: PMC8772587 DOI: 10.1039/d1bm01539g] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Pediatric patients with congenital heart defects (CHD) often present with heart failure from increased load on the right ventricle (RV) due to both surgical methods to treat CHD and the disease itself. Patients with RV failure often require transplantation, which is limited due to lack of donor availability and rejection. Previous studies investigating the development and in vitro assessment of a bioprinted cardiac patch composed of cardiac extracellular matrix (cECM) and human c-kit + progenitor cells (hCPCs) showed that the construct has promise in treating cardiac dysfunction. The current study investigates in vivo cardiac outcomes of patch implantation in a rat model of RV failure. Patch parameters including cECM-inclusion and hCPC-inclusion are investigated. Assessments include hCPC retention, RV function, and tissue remodeling (vascularization, hypertrophy, and fibrosis). Animal model evaluation shows that both cell-free and neonatal hCPC-laden cECM-gelatin methacrylate (GelMA) patches improve RV function and tissue remodeling compared to other patch groups and controls. Inclusion of cECM is the most influential parameter driving therapeutic improvements, with or without cell inclusion. This study paves the way for clinical translation in treating pediatric heart failure using bioprinted GelMA-cECM and hCPC-GelMA-cECM patches.
Collapse
Affiliation(s)
- Donald Bejleri
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr, Atlanta, GA, 30322, USA.
| | - Matthew J Robeson
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr, Atlanta, GA, 30322, USA.
| | - Milton E Brown
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr, Atlanta, GA, 30322, USA.
| | - Jervaughn Hunter
- Department of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, 2880 Torrey Pines Scenic Dr, La Jolla, CA, 92037, USA
| | - Joshua T Maxwell
- Division of Pediatric Cardiology, Department of Pediatrics, Emory University School of Medicine, 2015 Uppergate Dr, Atlanta, GA, 30322, USA
| | - Benjamin W Streeter
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr, Atlanta, GA, 30322, USA.
| | - Olga Brazhkina
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr, Atlanta, GA, 30322, USA.
| | - Hyun-Ji Park
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr, Atlanta, GA, 30322, USA.
| | - Karen L Christman
- Department of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, 2880 Torrey Pines Scenic Dr, La Jolla, CA, 92037, USA
| | - Michael E Davis
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr, Atlanta, GA, 30322, USA.
- Division of Pediatric Cardiology, Department of Pediatrics, Emory University School of Medicine, 2015 Uppergate Dr, Atlanta, GA, 30322, USA
| |
Collapse
|
6
|
Shakya P, Brown ME, Davis ME. Encapsulation of Pediatric Cardiac-Derived C-Kit + Cells in Cardiac Extracellular Matrix Hydrogel for Echocardiography-Directed Intramyocardial Injection in Rodents. Methods Mol Biol 2022; 2485:269-278. [PMID: 35618912 DOI: 10.1007/978-1-0716-2261-2_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Pediatric cardiac-derived c-kit+ cell therapies represent an innovative approach for cardiac tissue repair that have demonstrated promising improvements in recent studies and offer multiple benefits, such as easy isolation and autologous transplant. However, concerns about failure of engraftment and transient paracrine effects have thus far limited their use. To overcome these issues, an appropriate cell delivery vehicle such as a cardiac extracellular matrix (cECM) hydrogel can be utilized. This naturally derived biomaterial can support embedded cells, allowing for local diffusion of paracrine factors, and provide a healthy microenvironment for optimal cellular function. This protocol focuses on combining cardiac-derived c-kit+ cells and a cECM hydrogel to prepare a minimally invasive, dual therapeutic for in vivo delivery. We also outline a detailed method for ultrasound-guided intramyocardial injection of cell-laden hydrogels in a rodent model. Additional steps for labeling cells with a fluorescent dye for in vivo cell tracking are provided.
Collapse
Affiliation(s)
- Preety Shakya
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA
| | - Milton E Brown
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Michael E Davis
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
- Children's Heart Research and Outcomes (HeRO) Center, Children's Healthcare of Atlanta and Emory University, Atlanta, GA, USA.
| |
Collapse
|
7
|
Abstract
RATIONALE Mitochondrial Ca2+ loading augments oxidative metabolism to match functional demands during times of increased work or injury. However, mitochondrial Ca2+ overload also directly causes mitochondrial rupture and cardiomyocyte death during ischemia-reperfusion injury by inducing mitochondrial permeability transition pore opening. The MCU (mitochondrial Ca2+ uniporter) mediates mitochondrial Ca2+ influx, and its activity is modulated by partner proteins in its molecular complex, including the MCUb subunit. OBJECTIVE Here, we sought to examine the function of the MCUb subunit of the MCU-complex in regulating mitochondria Ca2+ influx dynamics, acute cardiac injury, and long-term adaptation after ischemic injury. METHODS AND RESULTS Cardiomyocyte-specific MCUb overexpressing transgenic mice and Mcub gene-deleted (Mcub-/-) mice were generated to dissect the molecular function of this protein in the heart. We observed that MCUb protein is undetectable in the adult mouse heart at baseline, but mRNA and protein are induced after ischemia-reperfusion injury. MCUb overexpressing mice demonstrated inhibited mitochondrial Ca2+ uptake in cardiomyocytes and partial protection from ischemia-reperfusion injury by reducing mitochondrial permeability transition pore opening. Antithetically, deletion of the Mcub gene exacerbated pathological cardiac remodeling and infarct expansion after ischemic injury in association with greater mitochondrial Ca2+ uptake. Furthermore, hindlimb remote ischemic preconditioning induced MCUb expression in the heart, which was associated with decreased mitochondrial Ca2+ uptake, collectively suggesting that induction of MCUb protein in the heart is protective. Similarly, mouse embryonic fibroblasts from Mcub-/- mice were more sensitive to Ca2+ overload. CONCLUSIONS Our studies suggest that Mcub is a protective cardiac inducible gene that reduces mitochondrial Ca2+ influx and permeability transition pore opening after ischemic injury to reduce ongoing pathological remodeling.
Collapse
Affiliation(s)
- Jiuzhou Huo
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (J.H., M.J.B., K.M.G., M.A.S., J.D.M.)
| | - Shan Lu
- Department of Pharmacology, University of California, Davis (S.L., D.M.B.)
| | - Jennifer Q Kwong
- Division of Pediatric Cardiology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA (J.Q.K.)
| | - Michael J Bround
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (J.H., M.J.B., K.M.G., M.A.S., J.D.M.)
| | - Kelly M Grimes
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (J.H., M.J.B., K.M.G., M.A.S., J.D.M.)
| | - Michelle A Sargent
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (J.H., M.J.B., K.M.G., M.A.S., J.D.M.)
| | - Milton E Brown
- Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine, Atlanta, GA (M.E.B., M.E.D.)
| | - Michael E Davis
- Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine, Atlanta, GA (M.E.B., M.E.D.)
| | - Donald M Bers
- Department of Pharmacology, University of California, Davis (S.L., D.M.B.)
| | - Jeffery D Molkentin
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (J.H., M.J.B., K.M.G., M.A.S., J.D.M.)
- Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, OH (J.D.M.)
| |
Collapse
|
8
|
Jing B, Brown ME, Davis ME, Lindsey BD. Imaging the Activation of Low-Boiling-Point Phase-Change Contrast Agents in the Presence of Tissue Motion Using Ultrafast Inter-frame Activation Ultrasound Imaging. Ultrasound Med Biol 2020; 46:1474-1489. [PMID: 32143861 PMCID: PMC7199438 DOI: 10.1016/j.ultrasmedbio.2020.01.029] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Revised: 01/23/2020] [Accepted: 01/26/2020] [Indexed: 05/13/2023]
Abstract
Nanoscale phase-change contrast agents (PCCAs) have been found to have great potential in non-invasive extravascular imaging and therapeutic delivery. However, the contrast-to-tissue ratio (CTR) of PCCA images is usually limited because of either physiological motion or incomplete cancelation of tissue signal. Therefore, to improve the CTR of PCCA images in the presence of physiological motion, a new imaging technique, ultrafast inter-frame activation ultrasound (UIAU) imaging, is proposed and validated. Results of studies with controlled motion in tissue-mimicking phantoms indicate UIAU could provide significantly higher CTRs (maximum: 17.3 ± 0.9 dB) relative to conventional pulse inversion imaging (maximum CTR: 3.4 ± 1.4 dB). UIAU has CTRs up to 16.1 ± 1.0 dB relative to 3.9 ± 2.3 dB for differential imaging in the presence of physiological motion at 20 mm/s. In vivo imaging of PCCAs in the rat liver also reveals the ability of UIAU to enhance PCCA image contrast in the presence of physiological motion.
Collapse
Affiliation(s)
- Bowen Jing
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA
| | - Milton E Brown
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA
| | - Michael E Davis
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA; Children's Heart Research & Outcomes Center, Children's Healthcare of Atlanta & Emory University, Atlanta, Georgia, USA; Division of Cardiology, Department of Medicine, Emory University, Atlanta, Georgia, USA
| | - Brooks D Lindsey
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA; School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
| |
Collapse
|
9
|
Maxwell JT, Trac D, Shen M, Brown ME, Davis ME, Chao MS, Supapannachart KJ, Zaladonis CA, Baker E, Li ML, Zhao J, Jacobs DI. Electrical Stimulation of pediatric cardiac-derived c-kit + progenitor cells improves retention and cardiac function in right ventricular heart failure. Stem Cells 2019; 37:1528-1541. [PMID: 31574184 PMCID: PMC6916193 DOI: 10.1002/stem.3088] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Revised: 07/18/2019] [Accepted: 08/29/2019] [Indexed: 12/20/2022]
Abstract
Nearly 1 in every 120 children born has a congenital heart defect. Although surgical therapy has improved survival, many of these children go on to develop right ventricular heart failure (RVHF). The emergence of cardiovascular regenerative medicine as a potential therapeutic strategy for pediatric HF has provided new avenues for treatment with a focus on repairing or regenerating the diseased myocardium to restore cardiac function. Although primarily tried using adult cells and adult disease models, stem cell therapy is relatively untested in the pediatric population. Here, we investigate the ability of electrical stimulation (ES) to enhance the retention and therapeutic function of pediatric cardiac-derived c-kit+ progenitor cells (CPCs) in an animal model of RVHF. Human CPCs isolated from pediatric patients were exposed to chronic ES and implanted into the RV myocardium of rats. Cardiac function and cellular retention analysis showed electrically stimulated CPCs (ES-CPCs) were retained in the heart at a significantly higher level and longer time than control CPCs and also significantly improved right ventricular functional parameters. ES also induced upregulation of extracellular matrix and adhesion genes and increased in vitro survival and adhesion of cells. Specifically, upregulation of β1 and β5 integrins contributed to the increased retention of ES-CPCs. Lastly, we show that ES induces CPCs to release higher levels of pro-reparative factors in vitro. These findings suggest that ES can be used to increase the retention, survival, and therapeutic effect of human c-kit+ progenitor cells and can have implications on a variety of cell-based therapies. Stem Cells 2019;37:1528-1541.
Collapse
Affiliation(s)
- Joshua T. Maxwell
- Division of Pediatric Cardiology, Department of PediatricsEmory University School of MedicineAtlantaGeorgiaUSA
- Children's Heart Research & Outcomes (HeRO) CenterChildren's Healthcare of Atlanta & Emory UniversityAtlantaGeorgiaUSA
| | - David Trac
- Wallace H. Coulter Department of Biomedical EngineeringGeorgia Institute of Technology & Emory University School of MedicineAtlantaGeorgiaUSA
| | - Ming Shen
- Division of Pediatric Cardiology, Department of PediatricsEmory University School of MedicineAtlantaGeorgiaUSA
- Children's Heart Research & Outcomes (HeRO) CenterChildren's Healthcare of Atlanta & Emory UniversityAtlantaGeorgiaUSA
| | - Milton E. Brown
- Wallace H. Coulter Department of Biomedical EngineeringGeorgia Institute of Technology & Emory University School of MedicineAtlantaGeorgiaUSA
| | - Michael E. Davis
- Division of Pediatric Cardiology, Department of PediatricsEmory University School of MedicineAtlantaGeorgiaUSA
- Children's Heart Research & Outcomes (HeRO) CenterChildren's Healthcare of Atlanta & Emory UniversityAtlantaGeorgiaUSA
- Wallace H. Coulter Department of Biomedical EngineeringGeorgia Institute of Technology & Emory University School of MedicineAtlantaGeorgiaUSA
| | - Myra S. Chao
- Emory University College of Arts and SciencesAtlantaGeorgiaUSA
| | | | | | - Emily Baker
- Emory University College of Arts and SciencesAtlantaGeorgiaUSA
| | - Martin L. Li
- Emory University College of Arts and SciencesAtlantaGeorgiaUSA
| | - Jennifer Zhao
- Cornell University College of Arts and SciencesIthacaNew YorkUSA
| | | |
Collapse
|
10
|
Sayegh MN, Wang L, Shin EY, Han WM, Brown ME, Davis ME, Garcia AJ, Levit RD. Abstract 146: Investigating and Inhibiting Neutrophil Extracellular Trap Formation in the Heart. Circ Res 2019. [DOI: 10.1161/res.125.suppl_1.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Neutrophil extracellular traps (NETs) have been observed in multiple diseases of the cardiovascular system, such as myocardial infarction and atherosclerosis. We have recently shown that adenosine (ADO) inhibits NET formation and may be an important endogenous regulator. CD73 is expressed on many cell types and catalyzes the extracellular formation of ADO from AMP. Here, we first attempt to implicate NETs in cardiac injury, and we posit that human NETs negatively impact cardiac function by influencing native leukocyte recruitment and activation. Second, we prototype a CD73-functionalized hydrogel delivery vehicle for adenosine and test its function in vitro. We introduced NETs obtained from stimulated neutrophils into healthy hearts by intramyocardial injection in two-month-old rats. We used echo to assess cardiac function at days 0, 1 and 3 of injection. We measured the abundance of cardiac leukocyte subpopulations by flow cytometry at days 1 and 3 after injection, with immunostaining for CD45 (all leukocytes), myeloperoxidase (MPO, neutrophils), CD68 (macrophages), CD3 (T-cells), B220 (B-cells) and citrullinated histone 3 (citH3, NETs). To deliver adenosine as a NET antagonist, we designed a polyethylene (PEG) hydrogel composed of a 4-armed PEG incorporating a VPM protease-degradable crosslinker for cargo release, and an RGD peptide to enhance gel-tissue attachment. We tested gel polymerization by measuring storage and loss moduli at 4% and 6% PEG content (w/v) and 0, 1 uM and 1mM RGD concentrations. We functionalized the gel with CD73 to test its adenosine production capability. We found a significant decreased in cardiac function assessed by global longitudinal strain at day 1 in the NET group compared to saline. By flow cytometry, we found an increase in neutrophils, macrophages and NET formation at day 1, while B- and T-cells were increased at day 3. We found that increasing the PEG content of our hydrogel, but not RGD, increases gel stiffness. We also found that the CD73 functionalized hydrogel successfully catalyzes the formation of adenosine in vitro. In conclusion, we found that NETs negatively impact cardiac function, and successfully tested an adenosine hydrogel source in vitro. Next, we will study the effect of our gel on NETs in vivo.
Collapse
|
11
|
Trac D, Maxwell JT, Brown ME, Xu C, Davis ME. Aggregation of Child Cardiac Progenitor Cells Into Spheres Activates Notch Signaling and Improves Treatment of Right Ventricular Heart Failure. Circ Res 2019; 124:526-538. [PMID: 30590978 PMCID: PMC6375764 DOI: 10.1161/circresaha.118.313845] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
RATIONALE Congenital heart disease can lead to life-threatening right ventricular (RV) heart failure. Results from clinical trials support expanding cardiac progenitor cell (CPC) based therapies. However, our recent data show that CPCs lose function as they age, starting as early as 1 year. OBJECTIVE To determine whether the aggregation of child (1-5-year-old) CPCs into scaffold-free spheres can improve differentiation by enhancing Notch signaling, a known regulator of CPC fate. We hypothesized that aggregated (3-dimensional [3D]) CPCs will repair RV heart failure better than monolayer (2-dimensional [2D]) CPCs. METHODS AND RESULTS Spheres were produced with 1500 CPCs each using a microwell array. CPC aggregation significantly increased gene expression of Notch1 compared with 2D CPCs, accompanied by significant upregulation of cardiogenic transcription factors (GATA4, HAND1, MEF2C, NKX2.5, and TBX5) and endothelial markers (CD31, FLK1, FLT1, VWF). Blocking Notch receptor activation with the γ-secretase inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) diminished these effects. To evaluate the therapeutic improvements of CPC aggregation, RV heart failure was induced in athymic rats by pulmonary artery banding, and cells were implanted into the RV free wall. Echocardiographic measurements 28 days postimplantation showed significantly improved RV function with 3D compared with 2D CPCs. Tracking implanted CPCs via DiR (1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide)-labeling showed improved retention of 3D CPCs. Transducing 3D CPCs with Notch1-shRNA (short hairpin RNA) did not reduce retention, but significantly reduced RV functional improvements. Histological analyses showed 3D treatment reduced RV fibrosis and increased angiogenesis. Although 3D CPCs formed CD31+ vessel-like cells in vivo, these effects are more likely because of improved 3D CPC exosome function compared with 2D CPC exosomes. CONCLUSIONS Spherical aggregation improves child CPC function in a Notch-dependent manner. The strong reparative ability of CPC spheres warrants further investigation as a treatment for pediatric heart failure, especially in older children where reparative ability may be reduced.
Collapse
Affiliation(s)
- David Trac
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, Atlanta, Georgia, 30322, USA
| | - Joshua T. Maxwell
- Division of Pediatric Cardiology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, 30322, USA
| | - Milton E. Brown
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, Atlanta, Georgia, 30322, USA
| | - Chunhui Xu
- Division of Pediatric Cardiology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, 30322, USA;,Children’s Heart Research & Outcomes (HeRO) Center, Children’s Healthcare of Atlanta & Emory University, Atlanta, Georgia, 30322, USA
| | - Michael E. Davis
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, Atlanta, Georgia, 30322, USA;,Division of Pediatric Cardiology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, 30322, USA;,Children’s Heart Research & Outcomes (HeRO) Center, Children’s Healthcare of Atlanta & Emory University, Atlanta, Georgia, 30322, USA
| |
Collapse
|
12
|
Bejleri D, Streeter BW, Nachlas ALY, Brown ME, Gaetani R, Christman KL, Davis ME. A Bioprinted Cardiac Patch Composed of Cardiac-Specific Extracellular Matrix and Progenitor Cells for Heart Repair. Adv Healthc Mater 2018; 7:e1800672. [PMID: 30379414 PMCID: PMC6521871 DOI: 10.1002/adhm.201800672] [Citation(s) in RCA: 147] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 10/16/2018] [Indexed: 12/12/2022]
Abstract
Congenital heart defects are present in 8 of 1000 newborns and palliative surgical therapy has increased survival. Despite improved outcomes, many children develop reduced cardiac function and heart failure requiring transplantation. Human cardiac progenitor cell (hCPC) therapy has potential to repair the pediatric myocardium through release of reparative factors, but therapy suffers from limited hCPC retention and functionality. Decellularized cardiac extracellular matrix hydrogel (cECM) improves heart function in animals, and human trials are ongoing. In the present study, a 3D-bioprinted patch containing cECM for delivery of pediatric hCPCs is developed. Cardiac patches are printed with bioinks composed of cECM, hCPCs, and gelatin methacrylate (GelMA). GelMA-cECM bioinks print uniformly with a homogeneous distribution of cECM and hCPCs. hCPCs maintain >75% viability and incorporation of cECM within patches results in a 30-fold increase in cardiogenic gene expression of hCPCs compared to hCPCs grown in pure GelMA patches. Conditioned media from GelMA-cECM patches show increased angiogenic potential (>2-fold) over GelMA alone, as seen by improved endothelial cell tube formation. Finally, patches are retained on rat hearts and show vascularization over 14 d in vivo. This work shows the successful bioprinting and implementation of cECM-hCPC patches for potential use in repairing damaged myocardium.
Collapse
Affiliation(s)
- Donald Bejleri
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr., Atlanta, GA, 30322, USA
| | - Benjamin W Streeter
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr., Atlanta, GA, 30322, USA
| | - Aline L Y Nachlas
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr., Atlanta, GA, 30322, USA
| | - Milton E Brown
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr., Atlanta, GA, 30322, USA
| | - Roberto Gaetani
- Department of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, 2880 Torrey Pines Scenic Dr., La Jolla, CA, 92037, USA
| | - Karen L Christman
- Department of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, 2880 Torrey Pines Scenic Dr., La Jolla, CA, 92037, USA
| | - Michael E Davis
- Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr., Atlanta, GA, 30322, USA
| |
Collapse
|
13
|
Martinez MD, Trac DQ, Brown ME, Maher KO, Davis ME. Identification of targeting peptides for the diagnosis of myocarditis. Nanomedicine (Lond) 2018; 13:787-801. [DOI: 10.2217/nnm-2018-0023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Aim: Current diagnostic tests for myocarditis are invasive and have low diagnostic value. Our aim was to identify potential targeting peptides to detect early myocarditis following intravenous delivery. Materials & methods: We used an animal model of experimental autoimmune myocarditis and a phage display library to identify potential targeting peptides. After several steps, we selected two peptides, MyH-PhD-05 and MyH-PhD-120, for in vivo screening using fluorescent imaging. Immunofluorescence and proteonomic analysis was used to identify potential cellular and molecular targets of MyH-PhD-05. Echocardiography was used to assess functional changes. Results: Peptide MyH-PhD-05 was able to detect animals with severe myocarditis even in the absence of functional changes. Immunofluorescence demonstrated that MyH-PhD-05 colocalizes with CD4+ T cells and monocytes (CD11b+) in cardiac infiltrates. Conclusion: We identified potential targeting peptides for the diagnosis of myocarditis. Future studies will focus on better identification of potential targets and translating this technology to clinically relevant imaging modalities.
Collapse
Affiliation(s)
- Mario D Martinez
- Wallace H Coulter Department of Biomedical Engineering, Emory University & Georgia Institute of Technology, Atlanta, GA 30322, USA
| | - David Q Trac
- Wallace H Coulter Department of Biomedical Engineering, Emory University & Georgia Institute of Technology, Atlanta, GA 30322, USA
| | - Milton E Brown
- Wallace H Coulter Department of Biomedical Engineering, Emory University & Georgia Institute of Technology, Atlanta, GA 30322, USA
| | - Kevin O Maher
- Children's Heart Research & Outcomes Center, Children's Healthcare of Atlanta & Emory University, Atlanta, GA 30322, USA
| | - Michael E Davis
- Wallace H Coulter Department of Biomedical Engineering, Emory University & Georgia Institute of Technology, Atlanta, GA 30322, USA
- Children's Heart Research & Outcomes Center, Children's Healthcare of Atlanta & Emory University, Atlanta, GA 30322, USA
- Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA 30322, USA
| |
Collapse
|
14
|
Bhutani S, Nachlas ALY, Brown ME, Pete T, Johnson CT, García AJ, Davis ME. Evaluation of Hydrogels Presenting Extracellular Matrix-Derived Adhesion Peptides and Encapsulating Cardiac Progenitor Cells for Cardiac Repair. ACS Biomater Sci Eng 2017; 4:200-210. [PMID: 29457128 DOI: 10.1021/acsbiomaterials.7b00502] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Cell therapy is an emerging paradigm for the treatment of heart disease. In spite of the exciting and promising preclinical results, the benefits of cell therapy for cardiac repair in patients have been modest at best. Biomaterials-based approaches may overcome the barriers of poor differentiation and retention of transplanted cells. In this study, we prepared and tested hydrogels presenting extracellular matrix (ECM)-derived adhesion peptides as delivery vehicles for c-kit+ cardiac progenitor cells (CPCs). We assessed their effects on cell behavior in vitro as well as cardiac repair in rats undergoing ischemia reperfusion. Hydrogels presenting the collagen-derived GFOGER peptide induced cardiomyocyte differentiation of CPCs as demonstrated by increased expression of cardiomyocyte structural proteins. However, conditioned media obtained from GFOGER hydrogels showed lower levels of secreted reparative factors. Interestingly, following injection in rats undergoing ischemia-reperfusion, treatment with CPCs encapsulated in nonadhesive RDG-presenting hydrogels resulted in the preservation of cardiac contractility and attenuation of postinfarct remodeling whereas the adhesion peptide-presenting hydrogels did not induce any functional improvement. Retention of cells was significantly higher when delivered with nonadhesive hydrogels compared to ECM-derived peptide gels. These data suggest that factors including cell differentiation state, paracrine factors and interaction with biomaterials influence the effectiveness of biomaterials-based cell therapy. A holistic consideration of these multiple variables should be included in cell-biomaterial combination therapy designs.
Collapse
Affiliation(s)
- Srishti Bhutani
- Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, 1760 Haygood Drive, W200, Atlanta, Georgia 30322, United States
| | - Aline L Y Nachlas
- Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, 1760 Haygood Drive, W200, Atlanta, Georgia 30322, United States
| | - Milton E Brown
- Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, 1760 Haygood Drive, W200, Atlanta, Georgia 30322, United States
| | - Tionne Pete
- Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, 1760 Haygood Drive, W200, Atlanta, Georgia 30322, United States
| | - Christopher T Johnson
- Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, 1760 Haygood Drive, W200, Atlanta, Georgia 30322, United States.,George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, 801 Ferst Drive, Atlanta, Georgia 30313, United States
| | - Andres J García
- George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, 801 Ferst Drive, Atlanta, Georgia 30313, United States.,Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, Georgia 30332, United States
| | - Michael E Davis
- Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, 1760 Haygood Drive, W200, Atlanta, Georgia 30322, United States.,George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, 801 Ferst Drive, Atlanta, Georgia 30313, United States.,Division of Cardiology, Emory University School of Medicine, 101 Woodruff Circle, Room 319, Atlanta, Georgia 30322, United States.,Children's Heart Research and Outcomes Center, Children's Healthcare of Atlanta, 1760 Haygood Drive, W400, Atlanta, Georgia 30322, United States
| |
Collapse
|
15
|
Yang J, Brown ME, Zhang H, Martinez M, Zhao Z, Bhutani S, Yin S, Trac D, Xi JJ, Davis ME. High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction. Am J Physiol Heart Circ Physiol 2017; 312:H1002-H1012. [PMID: 28235791 DOI: 10.1152/ajpheart.00685.2016] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 02/01/2017] [Accepted: 02/15/2017] [Indexed: 01/09/2023]
Abstract
Myocardial infarction (MI) is the most common cause of heart failure. Excessive production of ROS plays a key role in the pathogenesis of cardiac remodeling after MI. NADPH with NADPH oxidase (Nox)2 as the catalytic subunit is a major source of superoxide production, and expression is significantly increased in the infarcted myocardium, especially by infiltrating macrophages. While microRNAs (miRNAs) are potent regulators of gene expression and play an important role in heart disease, there still lacks efficient ways to identify miRNAs that target important pathological genes for treating MI. Thus, the overall objective was to establish a miRNA screening and delivery system for improving heart function after MI using Nox2 as a critical target. With the use of the miRNA-target screening system composed of a self-assembled cell microarray (SAMcell), three miRNAs, miR-106b, miR-148b, and miR-204, were identified that could regulate Nox2 expression and its downstream products in both human and mouse macrophages. Each of these miRNAs were encapsulated into polyketal (PK3) nanoparticles that could effectively deliver miRNAs into macrophages. Both in vitro and in vivo studies in mice confirmed that PK3-miRNAs particles could inhibit Nox2 expression and activity and significantly improve infarct size and acute cardiac function after MI. In conclusion, our results show that miR-106b, miR-148b, and miR-204 were able to improve heart function after myocardial infarction in mice by targeting Nox2 and possibly altering inflammatory cytokine production. This screening system and delivery method could have broader implications for miRNA-mediated therapeutics for cardiovascular and other diseases.NEW & NOTEWORTHY NADPH oxidase (Nox)2 is a promising target for treating cardiovascular disease, but there are no specific inhibitors. Finding endogenous signals that can target Nox2 and other inflammatory molecules is of great interest. In this study, we used high-throughput screening to identify microRNAs that target Nox2 and improve cardiac function after infarction.
Collapse
Affiliation(s)
- Junyu Yang
- Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, China.,Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia
| | - Milton E Brown
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia
| | - Hanshuo Zhang
- Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, China
| | - Mario Martinez
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia
| | - Zhihua Zhao
- Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, China
| | - Srishti Bhutani
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia
| | - Shenyi Yin
- Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, China
| | - David Trac
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia
| | - Jianzhong Jeff Xi
- Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, China.,Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia.,State Key Laboratory of Natural and Biomimetic Drugs, Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, China.,State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Molecular Medicine, Peking University, Beijing, China; and
| | - Michael E Davis
- Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, China; .,Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia.,Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
| |
Collapse
|
16
|
Paoletti C, Regan MM, Liu MC, Marcom PK, Hart LL, Smith JW, Tedesco KL, Amir E, Krop IE, DeMichele AM, Goodwin PJ, Block M, Aung K, Cannell EM, Darga EP, Baratta PJ, Brown ME, McCormack RT, Hayes DF. Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-01-01] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Only half of hormone receptor positive (HR+) metastatic breast cancer (MBC) patients (pts) benefit from endocrine therapy (ET). Circulating tumor cells (CTC) are prognostic in pts with MBC using CellSearch® technology. The CTC-endocrine therapy index (CTC-ETI) provides semi-quantitative analyses of CTC-ER (estrogen receptor), BCL2, HER2, and Ki67 expression. We hypothesized that CTC-ETI high (elevated CTC number and/or low expression of ER and BCL2, and high expression of HER2 and Ki-67) might predict resistance to ET in a prospective, multi-institutional clinical trial: COMETI-P2-2012.0 (NCT01701050).
Methods: 121 pts with ER+, HER2 negative (-), and progressive MBC after one or more lines of ET or within 12 months (mos) of completing adjuvant ET, who were initiating a new ET, were enrolled after informed consent. CTC and CTC-ETI were determined as previously reported (Paoletti C et al, CCR 2015) at baseline (BL), 1, 2, 3, and 12 mos, and/or at the time of progression. Imaging was performed every 3 mos. Association of CTC levels and CTC-ETI with patient outcomes (progression free survival (PFS); rapid progression (RP) defined as progression within 3 mos) was assessed using logrank and Fisher's exact tests. Trial design estimated 85 PFS and 51 RP events, providing >90% power (2-sided a=0.05); pts with unsuccessful BL CTC-ETI or ineligible were unevaluable. Only baseline (BL) data are reported in this abstract.
Results: 32% of enrolled pts had progression within 12 mos of completing adjuvant ET, whereas 40%, 20%, and 8% had 1, 2, ≥3 lines of ET for MBC. CTC-ETI was successfully determined in 93% of pts (90% CI, 88% to 97%). CTC were ≥5 CTC/7.5 ml whole blood in 37/108 (34%) pts evaluable for clinical validity. Elevated CTC was associated with worse PFS (median (m) PFS: 3.3 vs. 5.9 mos; P<0.01). Low, intermediate, and high CTC-ETI were observed in 75 (69%), 6 (6%), and 27 (25%) pts, respectively. CTC-ETI was associated with PFS (logrank P<0.01): pts with low, intermediate, and high CTC-ETI had mPFS of 5.7, 8.5, and 2.8 mos, respectively. In the 96 pts eligible for determination, elevated CTC was associated with RP, (65.6% vs. 42.2%; P=0.05) as was CTC-ETI (P=0.003): 79.2% (95% CI, 57.8% to 92.9%) of pts with high CTC-ETI had RP versus 41.2% (95% CI, 29.4% to 53.8%) with low CTC-ETI; in the small group with intermediate CTC-ETI 1 of 4 pts (25%) had RP.
Conclusions: In this multi-institutional, prospective study, CTC-ETI was accurately determined, confirming the previously established analytical validity of the assay, meeting the primary objective of the trial. Elevated CTC and CTC-ETI high compared to low were associated with poor outcomes to ET. CTC-ETI distribution resulted in a small number of patients assigned to the intermediate group, restricting our ability to associate this group with outcomes. These results suggest that CTC-biomarker phenotype and enumeration have clinical validity. CTC-ETI may identify ER+ HER2– MBC pts who are unlikely to benefit from ET and might be better treated with ET in combination with other therapies or proceed to chemotherapy. Further analyses including CTC-ETI at serial time points during ET are planned.
Citation Format: Paoletti C, Regan MM, Liu MC, Marcom PK, Hart LL, Smith II JW, Tedesco KL, Amir E, Krop IE, DeMichele AM, Goodwin PJ, Block M, Aung K, Cannell EM, Darga EP, Baratta PJ, Brown ME, McCormack RT, Hayes DF. Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-01-01.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - MM Regan
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - MC Liu
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - PK Marcom
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - LL Hart
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - JW Smith
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - KL Tedesco
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - E Amir
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - IE Krop
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - AM DeMichele
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - PJ Goodwin
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - M Block
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - K Aung
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - EM Cannell
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - EP Darga
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - PJ Baratta
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - ME Brown
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - RT McCormack
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| |
Collapse
|
17
|
Agarwal U, George A, Bhutani S, Ghosh-Choudhary S, Maxwell JT, Brown ME, Mehta Y, Platt MO, Liang Y, Sahoo S, Davis ME. Experimental, Systems, and Computational Approaches to Understanding the MicroRNA-Mediated Reparative Potential of Cardiac Progenitor Cell-Derived Exosomes From Pediatric Patients. Circ Res 2016; 120:701-712. [PMID: 27872050 DOI: 10.1161/circresaha.116.309935] [Citation(s) in RCA: 129] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Revised: 11/17/2016] [Accepted: 11/21/2016] [Indexed: 12/12/2022]
Abstract
RATIONALE Studies have demonstrated that exosomes can repair cardiac tissue post-myocardial infarction and recapitulate the benefits of cellular therapy. OBJECTIVE We evaluated the role of donor age and hypoxia of human pediatric cardiac progenitor cell (CPC)-derived exosomes in a rat model of ischemia-reperfusion injury. METHODS AND RESULTS Human CPCs from the right atrial appendages from children of different ages undergoing cardiac surgery for congenital heart defects were isolated and cultured under hypoxic or normoxic conditions. Exosomes were isolated from the culture-conditioned media and delivered to athymic rats after ischemia-reperfusion injury. Echocardiography at day 3 post-myocardial infarction suggested statistically improved function in neonatal hypoxic and neonatal normoxic groups compared with saline-treated controls. At 28 days post-myocardial infarction, exosomes derived from neonatal normoxia, neonatal hypoxia, infant hypoxia, and child hypoxia significantly improved cardiac function compared with those from saline-treated controls. Staining showed decreased fibrosis and improved angiogenesis in hypoxic groups compared with controls. Finally, using sequencing data, a computational model was generated to link microRNA levels to specific outcomes. CONCLUSIONS CPC exosomes derived from neonates improved cardiac function independent of culture oxygen levels, whereas CPC exosomes from older children were not reparative unless subjected to hypoxic conditions. Cardiac functional improvements were associated with increased angiogenesis, reduced fibrosis, and improved hypertrophy, resulting in improved cardiac function; however, mechanisms for normoxic neonatal CPC exosomes improved function independent of those mechanisms. This is the first study of its kind demonstrating that donor age and oxygen content in the microenvironment significantly alter the efficacy of human CPC-derived exosomes.
Collapse
Affiliation(s)
- Udit Agarwal
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.)
| | - Alex George
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.)
| | - Srishti Bhutani
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.)
| | - Shohini Ghosh-Choudhary
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.)
| | - Joshua T Maxwell
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.)
| | - Milton E Brown
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.)
| | - Yash Mehta
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.)
| | - Manu O Platt
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.)
| | - Yaxuan Liang
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.)
| | - Susmita Sahoo
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.)
| | - Michael E Davis
- From the Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (U.A., A.G., S.B., S.G.-C., J.T.M., M.E.B., Y.M., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (U.A., J.T.M., M.E.B., M.E.D.); Children's Heart Research and Outcomes Center, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.); and Cardiovascular Research Center, Icahn School of Medicine, Mount Sinai, New York (Y.L., S.S.).
| |
Collapse
|
18
|
Agarwal U, Smith AW, French KM, Boopathy AV, George A, Trac D, Brown ME, Shen M, Jiang R, Fernandez JD, Kogon BE, Kanter KR, Alsoufi B, Wagner MB, Platt MO, Davis ME. Age-Dependent Effect of Pediatric Cardiac Progenitor Cells After Juvenile Heart Failure. Stem Cells Transl Med 2016; 5:883-92. [PMID: 27151913 PMCID: PMC4922847 DOI: 10.5966/sctm.2015-0241] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2015] [Accepted: 02/08/2016] [Indexed: 12/31/2022] Open
Abstract
To investigate the role of age of human pediatric cardiac progenitor cells (hCPCs) on ventricular remodeling, the authors injected neonate, infant, or child hCPCs into rats with right ventricular heart failure. Mechanisms including migration and proliferation assays, as suggested by computational modeling, showed improved chemotactic and proliferative capacity of neonatal hCPCs compared with infant or child hCPCs. Thus, the reparative potential of hCPCs is age-dependent. Children with congenital heart diseases have increased morbidity and mortality, despite various surgical treatments, therefore warranting better treatment strategies. Here we investigate the role of age of human pediatric cardiac progenitor cells (hCPCs) on ventricular remodeling in a model of juvenile heart failure. hCPCs isolated from children undergoing reconstructive surgeries were divided into 3 groups based on age: neonate (1 day to 1 month), infant (1 month to 1 year), and child (1 to 5 years). Adolescent athymic rats were subjected to sham or pulmonary artery banding surgery to generate a model of right ventricular (RV) heart failure. Two weeks after surgery, hCPCs were injected in RV musculature noninvasively. Analysis of cardiac function 4 weeks post-transplantation demonstrated significantly increased tricuspid annular plane systolic excursion and RV ejection fraction and significantly decreased wall thickness and fibrosis in rats transplanted with neonatal hCPCs compared with saline-injected rats. Computational modeling and systems biology analysis were performed on arrays and gave insights into potential mechanisms at the microRNA and gene level. Mechanisms including migration and proliferation assays, as suggested by computational modeling, showed improved chemotactic and proliferative capacity of neonatal hCPCs compared with infant/child hCPCs. In vivo immunostaining further suggested increased recruitment of stem cell antigen 1-positive cells in the right ventricle. This is the first study to assess the role of hCPC age in juvenile RV heart failure. Interestingly, the reparative potential of hCPCs is age-dependent, with neonatal hCPCs exerting the maximum beneficial effect compared with infant and child hCPCs. Significance Stem cell therapy for children with congenital heart defects is moving forward, with several completed and ongoing clinical trials. Although there are studies showing how children differ from adults, few focus on the differences among children. This study using human cardiac progenitor cells shows age-related changes in the reparative ability of cells in a model of pediatric heart failure and uses computational and systems biology to elucidate potential mechanisms.
Collapse
Affiliation(s)
- Udit Agarwal
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA Division of Cardiology, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Amanda W Smith
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA Division of Cardiology, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Kristin M French
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA Division of Cardiology, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Archana V Boopathy
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA Division of Cardiology, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Alex George
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA
| | - David Trac
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA
| | - Milton E Brown
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA Division of Cardiology, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Ming Shen
- Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Rong Jiang
- Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Janet D Fernandez
- Department of Cardiothoracic Surgery, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Brian E Kogon
- Children's Healthcare of Atlanta, Atlanta, Georgia, USA
| | - Kirk R Kanter
- Children's Healthcare of Atlanta, Atlanta, Georgia, USA
| | | | - Mary B Wagner
- Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Manu O Platt
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA
| | - Michael E Davis
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA Division of Cardiology, School of Medicine, Emory University, Atlanta, Georgia, USA
| |
Collapse
|
19
|
Belvitch P, Dudek S, Brown ME, Garcia JG. ID: 131: ACTIN RELATED PROTEIN 2/3 COMPLEX REGULATES ACTIN MEMBRANE STRUCTURES TO DETERMINE ENDOTHELIAL BARRIER FUNCTION. J Investig Med 2016. [DOI: 10.1136/jim-2016-000120.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
RationaleDisruption of the pulmonary endothelial barrier is a hallmark feature of sepsis and acute lung injury/ARDS. Cytoskeletal structures such as the peripheral protrusive structures lamellipodia and filopodia are hypothesized to be important determinants of endothelial barrier function. The actin related protein 2/3 complex (Arp 2/3) is a key regulator of branched actin polymerization and may play a role in the determination and recovery of endothelial cell (EC) barrier integrity. In the current study, we make detailed observations of actin structures and membrane formations in the presence of a specific Arp 2/3 inhibitor. In addition, we study the subcellular co-localization of Arp 2/3 and cortactin, another known protein regulator of peripheral actin dynamics.MethodsCultured human lung microvascular endothelial cells (HLMVEC) were subjected to pre-treatment with the specific Arp 2/3 inhibitor (CK-666 50 µM) or vehicle (DMSO) x 1 hour. Cells were then treated with barrier enhancing sphingosine-1-phosphate (S1P 1 µM) or barrier disruptive thrombin (1 U/ml) and fixed at various time points (2–90 min) for subsequent imaging. Cells were permeabilized and treated with far-red phalloidin to stain actin, an anti-cortactin-GFP mAb as well as DAPI and imaged by confocal microscopy. Peripheral actin formations and associated membrane lamellipodia and filopodia were then measured and characterized. Additionally, the co-localization of Arp 2/3 and cortactin was determined.ResultsArp 2/3 inhibition markedly reduced lamellipodia formation in response to S1P (1 µM) over a range of time points (2–30 min). Lamellipodia depth was decreased in Arp 2/3 inhibited cells compared to control both at baseline (1.825 +/− 0.407 µM) vs. (2.545 +/− 0.459 µM) and following 30 min treatment with 1 µM S1P (1.534 +/− 0.365 µM) vs. (2.090 +/− 0.356 µM). Similarly, filopodia were shorter following Arp 2/3 inhibition (2.392 +/− 0.393 µM) vs. control (2.753 +/− 0.274 µM). Robust colocalization of Arp 2/3 and cortactin was observed very early (2–5 min) following S1P (1 µM) treatment in vehicle treated cells but was attenuated in the presence of the Arp 2/3 inhibitor. Following thrombin treatment (1 U/ml), peripheral lamellipodia were observed during the barrier recovery phase (30–60 min) but were markedly reduced following Arp 2/3 inhibition along with the persistence of intercellular gaps.ConclusionThese results further demonstrate the importance of the Arp 2/3 complex in pulmonary endothelial barrier integrity and recovery. These experiments also serve to relate the concept of altered peripheral actin and membrane dynamics leading to changes in EC barrier function.
Collapse
|
20
|
Paoletti C, Cani AK, Aung K, Darga EP, Cannell EM, Hovelson DH, Yazdani M, Blevins AR, Tokudome N, Larios JM, Thomas DG, Brown ME, Gersch C, Schott AF, Robinson DR, Chinnaiyan AM, Bischoff F, Hayes DF, Rae JM, Tomlins SA. Abstract P2-02-19: Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-02-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Somatic mutations, including those in TP53, PIK3CA, and estrogen receptor alpha (ESR1), are key to the biology of cancer and response to therapy. Recently, somatic cancer-associated mutations have been identified in circulating cell free plasma tumor DNA (ptDNA). Less is known about the mutation profile of DNA extracted from CTC (CTC-DNA). Since CTC-DNA provides mutational information of single cells, we hypothesize CTC-DNA will complement ptDNA to give greater insight into tumor heterogeneity.
Methods: Patients with ER positive MBC who were enrolled in the Mi CTC-ONCOSEQ, a companion trial to Mi-ONCOSEQ (the Michigan Oncology Sequencing Program), and who had ≥5CTC/7.5 ml whole blood were included. CTC were enriched from white blood cells (WBC) with CellSearch© (CXC kit). CTC and WBC were then purified using DEPArrayTM. DNA from individual CTC and WBC was isolated and subjected to whole genomic amplification (Ampli 1TM WGA). Genetic analysis was performed on individual CTC, pooled CTC and pooled WBC DNA by multiplexed PCR based targeted next generation sequencing (NGS) using the Oncomine Comprehensive Panel (targeting ∼130 onco- and tumor suppressor genes) and the Ion Torrent Proton. All patients had exome sequencing performed on research biopsies of metastases using an Illumina HiSeq 2500 platform.
Results: This pilot study was conducted using high quality DNA from two patients assessed to date. Both patients had lobular carcinoma and as expected harbored somatic, deleterious CDH1 (E-cadherin) mutations (frameshift and non-sense) in both research biopsy and CTC-DNA. These data supported our approach. Patient #1 was TP53 wild type in her research biopsy, but multiple CTC harbored somatic TP53 frame-shift mutations (Table). Patient #2 harbored an ESR1 Y537S mutation in her research biopsy. However, only 4 of 7 CTC also harbored this somatic, heterozygous mutation.
Prioritized mutations in CTCPt#Cell Type (CTC vs WBC), numberGeneMutationVariant fraction (expected 1=homozygous; 0.5=heterozygous)Found in research biopsy?1CTC_A2CDH1p.I584fs1YES CTC_A4 1 CTC_A7 0.54 CTC_pool* 0.74 WBC_pool 0 CTC_A2TP53p.152_156del1NO CTC_A4 1 CTC_A7 0.51 CTC_pool* 0.88 WBC_pool 0 2CTC_A9ESR1p.Y537S0.52YES CTC_D1 0.34 CTC_D2 0.46 CTC_D6 0.65 CTC_pool* 0.35 WBC_pool 0 CTC_A12 0 CTC_D3 0 CTC_D7 0 CTC_A12CDH1p.Q641X1YES CTC_A9 1 CTC_D1 1 CTC_D3 1 CTC_D6 1 CTC_pool* 1 WBC_pool 0 * pool of all CTC
Conclusions: We demonstrate the ability to purify CTC, isolate, and amplify DNA of suitable quality for genetic analysis using a comprehensive targeted sequencing panel. Both known and novel alterations were identified in comparison to research biopsy specimens. This approach allows single cell analysis demonstrating heterogeneity of mutational status in different single cells. Studies of CTC-ESR1 and other genetic abnormalities in patients with known tissue mutations who participated in Mi CTC-ONCOSEQ are now underway.
Citation Format: Paoletti C, Cani AK, Aung K, Darga EP, Cannell EM, Hovelson DH, Yazdani M, Blevins AR, Tokudome N, Larios JM, Thomas DG, Brown ME, Gersch C, Schott AF, Robinson DR, Chinnaiyan AM, Bischoff F, Hayes DF, Rae JM, Tomlins SA. Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-02-19.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AK Cani
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - K Aung
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - EP Darga
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - EM Cannell
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DH Hovelson
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - M Yazdani
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AR Blevins
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - N Tokudome
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - JM Larios
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - ME Brown
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - C Gersch
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AF Schott
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DR Robinson
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AM Chinnaiyan
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - F Bischoff
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - JM Rae
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - SA Tomlins
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| |
Collapse
|
21
|
Paoletti C, Aung K, Cannell EM, Darga EP, Chu D, Kidwell KM, Thomas DG, Tokudome N, Brown ME, McNutt LM, Gersch C, Schott AF, Park BH, Robinson DR, Chinnaiyan AM, Rae JM, Hayes DF. Abstract P3-05-01: Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-05-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Fifty percent of ER positive MBC patients do not benefit from ET. Potential mechanisms of resistance to ET in this patient population include absence of ER expression by deletion or suppression, alteration in ER signaling pathway genes, or upregulation of multiple growth factor receptor pathways. We hypothesized that genotyping and phenotyping of CTC combined with genomic analysis of ptDNA will provide important insights into the multiple mechanisms of ET resistance and that a set of blood tests might serve as a "liquid biopsy" abrogating the need for tissue specimens.
Methods: Twenty-four patients providing informed consent were enrolled into the Mi CTC-ONCOSEQ study, a companion trial to Mi-ONCOSEQ (the Michigan Oncology Sequencing Program). Seven of these patients (5 with ER immunohistochemistry (IHC) positive and 2 with ER negative cancers) who had available archived primary and metastatic cancer tissue, a research metastatic biopsy for genomic analysis, and who had ≥5CTC/7.5 ml whole blood (WB) characterized for ER protein (CTC-ER) are the focus of this report. All the patients were ET refractory. None of them was progressing on fulvestrant at the time of study entry. CTC enumeration and phenotyping was performed with CellSearch©. Circulating ptDNA was analyzed by droplet digital polymerase chain reaction (ddPCR). ER status from archived tissue was obtained from chart review. ER mRNA expression was determined in the research biopsy of metastatic tissue by using quantitative RNA sequencing. Mutational status of ER gene, ESR1, was determined by Next-gen Sequencing using the Illumina HiSeq 2500 platform.
Results: The 2 control patients with triple negative breast cancer had negative CTC-ER. Discordance between CTC-ER and tissue ER by IHC was observed (Table). Two of the 5 ER positive patients retained CTC-ER positivity (39% and 19% of the CTC). One of them (#7) harbored an ESR1 mutation in the research biopsy tissue and in ptDNA, whereas the other (#14) had wild type (WT) ESR1. CTC-ER protein levels in patients #12, 17 and 24 were negative. All had WT ESR1 in the research biopsy tissue. Of note, patient #12 had WT ESR1 in the research biopsy, but an ESR1 mutation was detected in her ptDNA.
Pt#CTC-ER Tissue-ER ESR1 status in research biopsyESR1 status in ptDNA N[deg]CTC/7.5ml WB% CTC-ER +Primary by IHCMet by IHCMet research biopsy by mRNA 71839%+++Y537SY537S141619%+NA+WTWT12130%+++WTD538G17160%++weakly+WTWT242750%+weakly+weakly+WTWT
Conclusions: These exploratory data suggest heterogeneous mechanisms of resistance to ET in patients with previously determined ER-positive MBC, including ESR1 mutations in ER positive cases (seen in 2 patients) and loss of ER expression (seen in CTC of 3 patients). In contrast, other cancers continue to express WT ESR1, and therefore must have developed alternative mechanisms of resistance. At least 2 of these mechanisms can be detected and monitored with complementary circulating assays: CTC and ptDNA. Further investigations are needed to understand the heterogeneous mechanisms of resistance to ET.
Citation Format: Paoletti C, Aung K, Cannell EM, Darga EP, Chu D, Kidwell KM, Thomas DG, Tokudome N, Brown ME, McNutt LM, Gersch C, Schott AF, Park BH, Robinson DR, Chinnaiyan AM, Rae JM, Hayes DF. Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-05-01.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - K Aung
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - EM Cannell
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - EP Darga
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - D Chu
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - KM Kidwell
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - N Tokudome
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - ME Brown
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - LM McNutt
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - C Gersch
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - AF Schott
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - BH Park
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - DR Robinson
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - AM Chinnaiyan
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - JM Rae
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| |
Collapse
|
22
|
Sackett SD, Brown ME, Tremmel DM, Ellis T, Burlingham WJ, Odorico JS. Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation. Transplant Rev (Orlando) 2016; 30:61-70. [PMID: 26970668 DOI: 10.1016/j.trre.2016.02.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Accepted: 02/05/2016] [Indexed: 01/20/2023]
Abstract
Tissues derived from induced pluripotent stem cells (iPSCs) are a promising source of cells for building various regenerative medicine therapies; from simply transplanting cells to reseeding decellularized organs to reconstructing multicellular tissues. Although reprogramming strategies for producing iPSCs have improved, the clinical use of iPSCs is limited by the presence of unique human leukocyte antigen (HLA) genes, the main immunologic barrier to transplantation. In order to overcome the immunological hurdles associated with allogeneic tissues and organs, the generation of patient-histocompatible iPSCs (autologous or HLA-matched cells) provides an attractive platform for personalized medicine. However, concerns have been raised as to the fitness, safety and immunogenicity of iPSC derivatives because of variable differentiation potential of different lines and the identification of genetic and epigenetic aberrations that can occur during the reprogramming process. In addition, significant cost and regulatory barriers may deter commercialization of patient specific therapies in the short-term. Nonetheless, recent studies provide some evidence of immunological benefit for using autologous iPSCs. Yet, more studies are needed to evaluate the immunogenicity of various autologous and allogeneic human iPSC-derived cell types as well as test various methods to abrogate rejection. Here, we present perspectives of using allogeneic vs. autologous iPSCs for transplantation therapies and the advantages and disadvantages of each related to differentiation potential, immunogenicity, genetic stability and tumorigenicity. We also review the current literature on the immunogenicity of syngeneic iPSCs and discuss evidence that questions the feasibility of HLA-matched iPSC banks. Finally, we will discuss emerging methods of abrogating or reducing host immune responses to PSC derivatives.
Collapse
Affiliation(s)
- S D Sackett
- Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - M E Brown
- Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - D M Tremmel
- Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - T Ellis
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - W J Burlingham
- Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - J S Odorico
- Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
| |
Collapse
|
23
|
Somasuntharam I, Yehl K, Carroll SL, Maxwell JT, Martinez MD, Che PL, Brown ME, Salaita K, Davis ME. Knockdown of TNF-α by DNAzyme gold nanoparticles as an anti-inflammatory therapy for myocardial infarction. Biomaterials 2015; 83:12-22. [PMID: 26773660 DOI: 10.1016/j.biomaterials.2015.12.022] [Citation(s) in RCA: 84] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 12/19/2015] [Indexed: 12/16/2022]
Abstract
In this study, we used deoxyribozyme (DNAzyme) functionalized gold nanoparticles (AuNPs) to catalytically silence tumor necrosis factor-α (TNF-α) in vivo as a potential therapeutic for myocardial infarction (MI). Using primary macrophages as a model, we demonstrated 50% knockdown of TNF-α, which was not attainable using Lipofectamine-based approaches. Local injection of DNAzyme conjugated to gold particles (AuNPs) in the rat myocardium yielded TNF-α knockdown efficiencies of 50%, which resulted in significant anti-inflammatory effects and improvement in acute cardiac function following MI. Our results represent the first example showing the use of DNAzyme AuNP conjugates in vivo for viable delivery and gene regulation. This is significant as TNF-α is a multibillion dollar drug target implicated in many inflammatory-mediated disorders, thus underscoring the potential impact of DNAzyme-conjugated AuNPs.
Collapse
Affiliation(s)
- Inthirai Somasuntharam
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 1760 Haygood Drive, Suite W200, Atlanta, GA 30322, USA; Division of Cardiology, Emory University School of Medicine, 101 Woodruff Circle Room 319, Atlanta, GA 30322, USA
| | - Kevin Yehl
- Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, GA 30322, USA
| | - Sheridan L Carroll
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 1760 Haygood Drive, Suite W200, Atlanta, GA 30322, USA
| | - Joshua T Maxwell
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 1760 Haygood Drive, Suite W200, Atlanta, GA 30322, USA
| | - Mario D Martinez
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 1760 Haygood Drive, Suite W200, Atlanta, GA 30322, USA
| | - Pao-Lin Che
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 1760 Haygood Drive, Suite W200, Atlanta, GA 30322, USA
| | - Milton E Brown
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 1760 Haygood Drive, Suite W200, Atlanta, GA 30322, USA; Division of Cardiology, Emory University School of Medicine, 101 Woodruff Circle Room 319, Atlanta, GA 30322, USA
| | - Khalid Salaita
- Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, GA 30322, USA.
| | - Michael E Davis
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 1760 Haygood Drive, Suite W200, Atlanta, GA 30322, USA; Division of Cardiology, Emory University School of Medicine, 101 Woodruff Circle Room 319, Atlanta, GA 30322, USA.
| |
Collapse
|
24
|
Boopathy AV, Martinez MD, Smith AW, Brown ME, García AJ, Davis ME. Intramyocardial Delivery of Notch Ligand-Containing Hydrogels Improves Cardiac Function and Angiogenesis Following Infarction. Tissue Eng Part A 2015; 21:2315-22. [PMID: 25982380 DOI: 10.1089/ten.tea.2014.0622] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Myocardial infarction (MI) is the leading cause of death worldwide. Notch1 signaling plays a critical role in cardiac development, in survival, cardiogenic lineage commitment, differentiation of cardiac stem/progenitor cells, and in regenerative responses following myocardial injury. The objective of this study was the evaluation of the therapeutic effect of delivering the Notch ligand-containing hydrogels in a rat model of MI. Self-assembling peptide (SAP) hydrogels were functionalized with a peptide mimic of the Notch1 ligand Jagged1 (RJ). In rats subjected to experimental MI, delivery of RJ-containing hydrogel to the infarcted heart resulted in improvement in cardiac function back to sham-operated levels. A significant decrease in fibrosis and an increase in the endothelial vessel area and Ki67 expression were also observed in rats treated with the RJ hydrogels compared to untreated rats or rats treated with unmodified or scrambled peptide hydrogels. This study demonstrates the functional benefit of Notch1-activating peptide delivered in SAP hydrogels for cardiac repair.
Collapse
Affiliation(s)
- Archana V Boopathy
- 1 Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology , Atlanta, Georgia .,2 Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology , Atlanta, Georgia .,3 Children's Heart Research and Outcomes Center, Children's Healthcare of Atlanta and Emory University , Atlanta, Georgia
| | - Mario D Martinez
- 1 Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology , Atlanta, Georgia .,3 Children's Heart Research and Outcomes Center, Children's Healthcare of Atlanta and Emory University , Atlanta, Georgia .,4 Division of Cardiology, Emory University School of Medicine , Atlanta, Georgia
| | - Amanda Walker Smith
- 1 Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology , Atlanta, Georgia .,3 Children's Heart Research and Outcomes Center, Children's Healthcare of Atlanta and Emory University , Atlanta, Georgia
| | - Milton E Brown
- 1 Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology , Atlanta, Georgia .,3 Children's Heart Research and Outcomes Center, Children's Healthcare of Atlanta and Emory University , Atlanta, Georgia .,4 Division of Cardiology, Emory University School of Medicine , Atlanta, Georgia
| | - Andrés J García
- 1 Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology , Atlanta, Georgia .,2 Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology , Atlanta, Georgia .,5 George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology , Atlanta, Georgia
| | - Michael E Davis
- 1 Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology , Atlanta, Georgia .,2 Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology , Atlanta, Georgia .,3 Children's Heart Research and Outcomes Center, Children's Healthcare of Atlanta and Emory University , Atlanta, Georgia .,4 Division of Cardiology, Emory University School of Medicine , Atlanta, Georgia
| |
Collapse
|
25
|
Gray WD, French KM, Ghosh-Choudhary S, Maxwell JT, Brown ME, Platt MO, Searles CD, Davis ME. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res 2014; 116:255-63. [PMID: 25344555 DOI: 10.1161/circresaha.116.304360] [Citation(s) in RCA: 289] [Impact Index Per Article: 28.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
RATIONALE Myocardial infarction is a leading cause of death in developed nations, and there remains a need for cardiac therapeutic systems that mitigate tissue damage. Cardiac progenitor cells (CPCs) and other stem cell types are attractive candidates for treatment of myocardial infarction; however, the benefit of these cells may be as a result of paracrine effects. OBJECTIVE We tested the hypothesis that CPCs secrete proregenerative exosomes in response to hypoxic conditions. METHODS AND RESULTS The angiogenic and antifibrotic potential of secreted exosomes on cardiac endothelial cells and cardiac fibroblasts were assessed. We found that CPC exosomes secreted in response to hypoxia enhanced tube formation of endothelial cells and decreased profibrotic gene expression in TGF-β-stimulated fibroblasts, indicating that these exosomes possess therapeutic potential. Microarray analysis of exosomes secreted by hypoxic CPCs identified 11 miRNAs that were upregulated compared with exosomes secreted by CPCs grown under normoxic conditions. Principle component analysis was performed to identify miRNAs that were coregulated in response to distinct exosome-generating conditions. To investigate the cue-signal-response relationships of these miRNA clusters with a physiological outcome of tube formation or fibrotic gene expression, partial least squares regression analysis was applied. The importance of each up- or downregulated miRNA on physiological outcomes was determined. Finally, to validate the model, we delivered exosomes after ischemia-reperfusion injury. Exosomes from hypoxic CPCs improved cardiac function and reduced fibrosis. CONCLUSIONS These data provide a foundation for subsequent research of the use of exosomal miRNA and systems biology as therapeutic strategies for the damaged heart.
Collapse
Affiliation(s)
- Warren D Gray
- From the The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (W.D.G., K.M.F., S.G.-C., J.T.M., M.E.B., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (W.D.G., C.D.S., M.E.D.); Atlanta Veterans Administration Medical Center, Decatur, GA (C.D.S.); and Emory+Children's Center for Cardiovascular Biology, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.)
| | - Kristin M French
- From the The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (W.D.G., K.M.F., S.G.-C., J.T.M., M.E.B., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (W.D.G., C.D.S., M.E.D.); Atlanta Veterans Administration Medical Center, Decatur, GA (C.D.S.); and Emory+Children's Center for Cardiovascular Biology, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.)
| | - Shohini Ghosh-Choudhary
- From the The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (W.D.G., K.M.F., S.G.-C., J.T.M., M.E.B., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (W.D.G., C.D.S., M.E.D.); Atlanta Veterans Administration Medical Center, Decatur, GA (C.D.S.); and Emory+Children's Center for Cardiovascular Biology, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.)
| | - Joshua T Maxwell
- From the The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (W.D.G., K.M.F., S.G.-C., J.T.M., M.E.B., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (W.D.G., C.D.S., M.E.D.); Atlanta Veterans Administration Medical Center, Decatur, GA (C.D.S.); and Emory+Children's Center for Cardiovascular Biology, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.)
| | - Milton E Brown
- From the The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (W.D.G., K.M.F., S.G.-C., J.T.M., M.E.B., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (W.D.G., C.D.S., M.E.D.); Atlanta Veterans Administration Medical Center, Decatur, GA (C.D.S.); and Emory+Children's Center for Cardiovascular Biology, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.)
| | - Manu O Platt
- From the The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (W.D.G., K.M.F., S.G.-C., J.T.M., M.E.B., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (W.D.G., C.D.S., M.E.D.); Atlanta Veterans Administration Medical Center, Decatur, GA (C.D.S.); and Emory+Children's Center for Cardiovascular Biology, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.)
| | - Charles D Searles
- From the The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (W.D.G., K.M.F., S.G.-C., J.T.M., M.E.B., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (W.D.G., C.D.S., M.E.D.); Atlanta Veterans Administration Medical Center, Decatur, GA (C.D.S.); and Emory+Children's Center for Cardiovascular Biology, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.)
| | - Michael E Davis
- From the The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (W.D.G., K.M.F., S.G.-C., J.T.M., M.E.B., M.O.P., M.E.D.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (W.D.G., C.D.S., M.E.D.); Atlanta Veterans Administration Medical Center, Decatur, GA (C.D.S.); and Emory+Children's Center for Cardiovascular Biology, Emory University School of Medicine and Children's Healthcare of Atlanta, GA (M.E.D.).
| |
Collapse
|
26
|
Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson V, Irvin WJ, Lin NU, Liu M, Nanda R, Nangia J, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero A, Hayes DF. Abstract P1-04-01: Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Circulating Tumor cells (CTCs) are prognostic at baseline and first follow-up in patients with metastatic breast cancer (MBC). Using the most commonly used assay (CellSearch®), we have previously reported the ability to detect apoptotic vs. non-apoptotic CTCs in patients with MBC. However, there has been concern regarding the performance of the CellSearch® assay in patients with triple negative (TN) MBC. We hypothesized that CellSearch® is an effective assay in patients with TN MBC, and that CTC-apoptosis might further separate prognosis. Therefore, we studied CTCs in patients with TN MBC who participated in a prospective randomized phase II trial testing for activity of tigatuzumab (TIG) in combination with nanoparticle albumin-bound paclitaxel (nab-PAC) conducted by the Translational Breast Cancer Research Consortium (overall results reported by Forero A., et al, ASCO 2013).
Methods: Whole blood (WB) was drawn into a CellSave tube at baseline, day 15, and day 29 and CTC counts were determined using the CXC CellSearch® kit. Apoptosis was characterized by staining with a monoclonal antibody that detects a neo-epitope on fragmented cytokeratin (M-30) and independently by visual inspection (nucleic condensation and/or fragmentation, as well as granular cytokeratin). Association between levels of CTCs and CTC-apoptosis with the overall response rate (ORR) and progression free survival (PFS) at baseline, day 15, and day 29 was assessed using logistic regression, Kaplan Meier curves, and Cox proportional hazards modeling.
Results: Of the 60 patients entered into the trial, 52 were evaluable for CTCs. Of these, 19/52 (36.5%), 14/52 (26.9%), and 13/49 (26.5%) had elevated CTCs (≥5CTC/7.5 ml WB) at baseline, day 15, and day 29, respectively. Patients with elevated CTCs at each time point had worse PFS than patients with low or no CTCs. Hazard rates (HR) at baseline, day 15, and day 29 were 2.38 (95% CI: 1.27-4.45, p = 0.007), 2.87 (95% CI: 1.46-5.66, p = 0.002), and 3.40 (95% CI: 1.68-6.89, p = 0.001), respectively. The odds of overall response for those who had elevated CTCs compared to those who did not at baseline, day 15, and day 29, were 0.25 (95% CI: 0.073-0.81, p = 0.024), 0.18 (95% CI: 0.04-0.67, p = 0.014), and 0.06 (95% CI: 0.01-0.28, p = 0.001), respectively. There was no apparent prognostic effect comparing the degree of CTC-apoptosis vs. non-apoptosis.
Conclusions: Similar to observations in other intrinsic subgroups, CTCs were detected in a large fraction of TN MBC patients at baseline using CellSearch® assay, and reductions in CTC levels reflected response. In these homogenously prospectively enrolled TN MBC patients, regardless of treatment, CTCs are prognostic at baseline, day 15, and day 29. It does not appear that analysis of CTC-apoptosis is prognostic.
Supported by Susan G. Komen for the Cure, Veridex, LLC, Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale™ (DFH), Associazione Sandro Pitigliani and by a studentship from FIRC (CP), Triple Negative Breast Cancer Foundation, The AVON Foundation, and The Breast Cancer Research Foundation.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-04-01.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Y Li
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - MC Muñiz
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - KM Kidwell
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - K Aung
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - ME Brown
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - V Abramson
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - WJ Irvin
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - NU Lin
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - M Liu
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - R Nanda
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - J Nangia
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - AM Storniolo
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - TA Traina
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - C Vaklavas
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - CH Van Poznak
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - AC Wolff
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - A Forero
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| |
Collapse
|
27
|
Paoletti C, Muñiz MC, Aung K, Larios J, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, Hayes DF. Abstract PD6-4: Heterogeneity of expression of estrogen receptor by circulating tumor cells suggests diverse mechanisms of resistance to fulvestrant in metastatic breast cancer patients. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-pd6-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Fulvestrant is a selective estrogen receptor down-regulator (SERD). Recent studies have shown that the efficacy of fulvestrant is dose-related. However, at the higher dose (500 mg/month) most cancers develop resistance and progress. We previously reported expression of several markers, including estrogen receptor (ER) and BCL-2, on breast cancer circulating tumor cells (CTC) using CellSearch®. We now report pilot data showing inter-patient heterogeneity of these markers on CTC in patients with known ER positive breast cancer whose disease is progressing on fulvestrant.
Methods: We conducted a pilot trial to determine the analytical validity of measuring expression of markers of endocrine sensitivity (ER, BCL-2) or resistance (HER-2, Ki-67) with fluorescent-labeled antibodies using the CellSearch® system. Patients with ER positive metastatic breast cancer (MBC) whose disease was progressing on any type of therapy were eligible after signed informed consent. This report is limited to the subjects who were progressing on fulvestrant. Whole blood (WB) was characterized for CTC counts and each of the four molecular markers using the CXC CellSearch® kit.
Results: Of 50 enrolled patients, seven were progressing on fulvestrant. Two patients had no detectable CTC, while five patients had an average of ≥5 CTC/7.5 mL WB. Results are shown in a table below:
CTC-ERCTC-BCL-2Patient #Fulvestrant dose (mg/month)Days since last doseN CTC/7.5 mL of WB% of CTC-ER+N CTC/7.5 mL of WB% of CTC-BCL-2+295002880%110%4550028170%170%2250341010%714%850031812%1735%172507728%367%
These exploratory data suggest widely different mechanisms of resistance to fulvestrant in different patients with ER positive MBC. In two of the patients (29, 45) treated with 500 mg/month, both CTC-ER and CTC-BCL-2 expression were absent, suggesting no signaling through the ER pathway. We hypothesize either that fulvestrant was actively down-regulating ER, but the cancers had adopted other growth and survival pathways, or that ER negative, hormone-independent clones had evolved. In the other three cases, ER was clearly present with evidence of signaling, based on BCL-2 expression. Two of these patients (2, 17) were on the lower dose of fulvestrant, now considered to be less effective. However, the third (8) was on the higher dose and yet still had evidence of ER signaling. This observation suggests that some patients may benefit from even higher doses of SERD therapy.
Conclusions: These pilot results suggest heterogeneous biological or pharmacological mechanisms of resistance to SERD therapy. These data suggest that CTC-ER and CTC-BCL-2 expression could serve as pharmacodynamic monitoring tools for dose escalation of fulvestrant or other SERDs. Further molecular analysis might provide biological bases for resistance to fulvestrant.
Supported by Veridex, LLC, Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale™ (DFH), Associazione Sandro Pitigliani and by a studentship from FIRC (CP).
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD6-4.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - MC Muñiz
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - K Aung
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - J Larios
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - N Tokudome
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - ME Brown
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - MC Connelly
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - DA Chianese
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - AF Schott
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - NL Henry
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - JM Rae
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| |
Collapse
|
28
|
Levit RD, Landázuri N, Phelps EA, Brown ME, García AJ, Davis ME, Joseph G, Long R, Safley SA, Suever JD, Lyle AN, Weber CJ, Taylor WR. Cellular encapsulation enhances cardiac repair. J Am Heart Assoc 2013; 2:e000367. [PMID: 24113327 PMCID: PMC3835246 DOI: 10.1161/jaha.113.000367] [Citation(s) in RCA: 110] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Background Stem cells for cardiac repair have shown promise in preclinical trials, but lower than expected retention, viability, and efficacy. Encapsulation is one potential strategy to increase viable cell retention while facilitating paracrine effects. Methods and Results Human mesenchymal stem cells (hMSC) were encapsulated in alginate and attached to the heart with a hydrogel patch in a rat myocardial infarction (MI) model. Cells were tracked using bioluminescence (BLI) and cardiac function measured by transthoracic echocardiography (TTE) and cardiac magnetic resonance imaging (CMR). Microvasculature was quantified using von Willebrand factor staining and scar measured by Masson's Trichrome. Post‐MI ejection fraction by CMR was greatly improved in encapsulated hMSC‐treated animals (MI: 34±3%, MI+Gel: 35±3%, MI+Gel+hMSC: 39±2%, MI+Gel+encapsulated hMSC: 56±1%; n=4 per group; P<0.01). Data represent mean±SEM. By TTE, encapsulated hMSC‐treated animals had improved fractional shortening. Longitudinal BLI showed greatest hMSC retention when the cells were encapsulated (P<0.05). Scar size at 28 days was significantly reduced in encapsulated hMSC‐treated animals (MI: 12±1%, n=8; MI+Gel: 14±2%, n=7; MI+Gel+hMSC: 14±1%, n=7; MI+Gel+encapsulated hMSC: 7±1%, n=6; P<0.05). There was a large increase in microvascular density in the peri‐infarct area (MI: 121±10, n=7; MI+Gel: 153±26, n=5; MI+Gel+hMSC: 198±18, n=7; MI+Gel+encapsulated hMSC: 828±56 vessels/mm2, n=6; P<0.01). Conclusions Alginate encapsulation improved retention of hMSCs and facilitated paracrine effects such as increased peri‐infarct microvasculature and decreased scar. Encapsulation of MSCs improved cardiac function post‐MI and represents a new, translatable strategy for optimization of regenerative therapies for cardiovascular diseases.
Collapse
Affiliation(s)
- Rebecca D. Levit
- Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, 30322, GA (R.D.L., N.L., M.E.B., M.E.D., G.J., A.N.L., R.T.)
| | - Natalia Landázuri
- Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, 30322, GA (R.D.L., N.L., M.E.B., M.E.D., G.J., A.N.L., R.T.)
| | - Edward A. Phelps
- Woodruff School of Mechanical Engineering and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, 30332, GA (E.A.P., A.G.)
| | - Milton E. Brown
- Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, 30322, GA (R.D.L., N.L., M.E.B., M.E.D., G.J., A.N.L., R.T.)
| | - Andrés J. García
- Woodruff School of Mechanical Engineering and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, 30332, GA (E.A.P., A.G.)
| | - Michael E. Davis
- Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, 30322, GA (R.D.L., N.L., M.E.B., M.E.D., G.J., A.N.L., R.T.)
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, 30332, GA (M.E.D., J.D.S., R.T.)
| | - Giji Joseph
- Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, 30322, GA (R.D.L., N.L., M.E.B., M.E.D., G.J., A.N.L., R.T.)
| | - Robert Long
- Department of Radiology and Imaging Science, Emory University, Atlanta, 30322, GA (R.L., J.D.S.)
| | - Susan A. Safley
- Department of Surgery, Emory University, Atlanta, 30322, GA (S.A.S., C.J.W.)
| | - Jonathan D. Suever
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, 30332, GA (M.E.D., J.D.S., R.T.)
- Department of Radiology and Imaging Science, Emory University, Atlanta, 30322, GA (R.L., J.D.S.)
| | - Alicia N. Lyle
- Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, 30322, GA (R.D.L., N.L., M.E.B., M.E.D., G.J., A.N.L., R.T.)
| | - Collin J. Weber
- Department of Surgery, Emory University, Atlanta, 30322, GA (S.A.S., C.J.W.)
| | - W. Robert Taylor
- Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, 30322, GA (R.D.L., N.L., M.E.B., M.E.D., G.J., A.N.L., R.T.)
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, 30332, GA (M.E.D., J.D.S., R.T.)
- Cardiology Division, Atlanta Veterans Affairs Medical Center, Decatur, 30033, GA (R.T.)
- Correspondence to: W. Robert Taylor, MD, PhD, Division of Cardiology, Emory University School of Medicine, 101 Woodruff Circle, Suite 319 WMB, Atlanta, GA 30322. E‐mail:
| |
Collapse
|
29
|
Somasuntharam I, Boopathy AV, Khan RS, Martinez MD, Brown ME, Murthy N, Davis ME. Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials 2013; 34:7790-8. [PMID: 23856052 DOI: 10.1016/j.biomaterials.2013.06.051] [Citation(s) in RCA: 81] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Accepted: 06/26/2013] [Indexed: 11/19/2022]
Abstract
Myocardial infarction (MI) is the most common cause of heart failure (HF), the leading cause of death in the developed world. Oxidative stress due to excessive production of reactive oxygen species (ROS) plays a key role in the pathogenesis of cardiac remodeling leading to HF. NADPH oxidase with Nox2 as the catalytic subunit is a major source for cardiac ROS production. Nox2-NADPH expression is significantly increased in the infarcted myocardium, primarily in neutrophils, macrophages and myocytes. Moreover, mice lacking the Nox2 gene are protected from ischemic injury, implicating Nox2 as a potential therapeutic target. RNAi-mediated gene silencing holds great promise as a therapeutic owing to its high specificity and potency. However, in vivo delivery hurdles have limited its effective clinical use. Here, we demonstrate acid-degradable polyketal particles as delivery vehicles for Nox2-siRNA to the post-MI heart. In vitro, Nox2-siRNA particles are effectively taken up by macrophages and significantly knockdown Nox2 expression and activity. Following in vivo intramyocardial injection in experimental mice models of MI, Nox2-siRNA particles prevent upregulation of Nox2 and significantly recovered cardiac function. This study highlights the potential of polyketals as siRNA delivery vehicles to the MI heart and represents a viable therapeutic approach for targeting oxidative stress.
Collapse
Affiliation(s)
- Inthirai Somasuntharam
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA 30322, USA
| | | | | | | | | | | | | |
Collapse
|
30
|
Pendergrass KD, Boopathy AV, Seshadri G, Maiellaro-Rafferty K, Che PL, Brown ME, Davis ME. Acute preconditioning of cardiac progenitor cells with hydrogen peroxide enhances angiogenic pathways following ischemia-reperfusion injury. Stem Cells Dev 2013; 22:2414-24. [PMID: 23544670 DOI: 10.1089/scd.2012.0673] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
There are a limited number of therapies available to prevent heart failure following myocardial infarction. One novel therapy that is currently being pursued is the implantation of cardiac progenitor cells (CPCs); however, their responses to oxidative stress during differentiation have yet to be elucidated. The objective of this study was to determine the effect of hydrogen peroxide (H2O2) treatment on CPC differentiation in vitro, as well as the effect of H2O2 preconditioning before implantation following ischemia-reperfusion (I/R) injury. CPCs were isolated and cloned from adult rat hearts, and then cultured in the absence or presence of H2O2 for 2 or 5 days. CPC survival was assessed with Annexin V, and cellular differentiation was evaluated through mRNA expression for cardiogenic genes. We found that 100 μM H2O2 decreased serum withdrawal-induced apoptosis by at least 45% following both 2 and 5 days of treatment. Moreover, 100 μM H2O2 treatment for 2 days significantly increased endothelial and smooth muscle markers compared to time-matched untreated CPCs. However, continued H2O2 treatment significantly decreased these markers. Left ventricular cardiac function was assessed 28 days after I/R and I/R with the implantation of Luciferase/GFP(+) CPCs, which were preconditioned with 100 μM H2O2 for 2 days. Hearts implanted with Luciferase/GFP(+) CPCs had significant improvement in both positive and negative dP/dT over I/R. Furthermore, cardiac fibrosis was significantly decreased in the preconditioned cells versus both I/R alone and I/R with control cells. We also observed a significant increase in endothelial cell density in the preconditioned CPC hearts compared to untreated CPC hearts, which also coincided with a higher density of Luciferase(+) vessels. These findings suggest that preconditioning of CPCs with H2O2 for 2 days stimulates neoangiogenesis in the peri-infarct area following I/R injury and could be a viable therapeutic option to prevent heart failure.
Collapse
Affiliation(s)
- Karl D Pendergrass
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Emory University, Atlanta, Georgia 30322, USA
| | | | | | | | | | | | | |
Collapse
|
31
|
Schneider T, Graves SDB, Schaller EL, Brown ME. Polar methane accumulation and rainstorms on Titan from simulations of the methane cycle. Nature 2012; 481:58-61. [PMID: 22222747 DOI: 10.1038/nature10666] [Citation(s) in RCA: 103] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2011] [Accepted: 10/20/2011] [Indexed: 11/09/2022]
Abstract
Titan has a methane cycle akin to Earth's water cycle. It has lakes in polar regions, preferentially in the north; dry low latitudes with fluvial features and occasional rainstorms; and tropospheric clouds mainly (so far) in southern middle latitudes and polar regions. Previous models have explained the low-latitude dryness as a result of atmospheric methane transport into middle and high latitudes. Hitherto, no model has explained why lakes are found only in polar regions and preferentially in the north; how low-latitude rainstorms arise; or why clouds cluster in southern middle and high latitudes. Here we report simulations with a three-dimensional atmospheric model coupled to a dynamic surface reservoir of methane. We find that methane is cold-trapped and accumulates in polar regions, preferentially in the north because the northern summer, at aphelion, is longer and has greater net precipitation than the southern summer. The net precipitation in polar regions is balanced in the annual mean by slow along-surface methane transport towards mid-latitudes, and subsequent evaporation. In low latitudes, rare but intense storms occur around the equinoxes, producing enough precipitation to carve surface features. Tropospheric clouds form primarily in middle and high latitudes of the summer hemisphere, which until recently has been the southern hemisphere. We predict that in the northern polar region, prominent clouds will form within about two (Earth) years and lake levels will rise over the next fifteen years.
Collapse
Affiliation(s)
- T Schneider
- California Institute of Technology, Pasadena, California 91125, USA.
| | | | | | | |
Collapse
|
32
|
Paoletti C, Connelly MC, Chianese DA, Brown ME, Muñiz MC, Rae JM, Thomas DG, Hayes DF. P4-07-16: Development of Circulating Tumor Cell-Endocrine Therapy Index in Metastatic Breast Cancer Patients. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-07-16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Only ∼ 50% of patients (pts) with estrogen receptor (ER) positive metastatic breast cancer (MBC) benefit from endocrine therapy (ET). Currently only clinical judgment can be used to identify pts with endocrine-refractory MBC, who are better palliated with chemotherapy. Circulating Tumor Cells (CTC) are reliably enumerated using an automated immunomagnetic system (CellSearch®; Veridex LLC). High CTC levels predict rapid progression in pts with MBC. We have developed a multi-parameter assay, the CTC-Endocrine Therapy Index (CTC-ETI) using CellSearch® that may identify pts with ER positive MBC who are unlikely to benefit from ET and may be better served with chemotherapy. CTC-ETI scores are assigned based on CTC levels coupled with the relative percent and degree of marker positivity on the CTC. We report preliminary results from a pilot single institutional study.
Methods: CellSearch® has 4 fluorescence channels. Three distinguish CTC from WBC (DAPI, anti-cytokeratin, anti-CD45). The 4th “empty” channel was used to measure ER, BCL-2, HER-2, and Ki-67 expression with fluorescent-labeled antibodies. These 4 markers reflect sensitivity (ER, BCL-2) or resistance (HER-2, Ki-67) to ET. Forty ml of blood was drawn into 4 CellSave® tubes from pts with progressive MBC. Whole blood from 4 tubes was pooled and divided into 4 different 7.5 ml aliquots of blood, which were processed and characterized for CTC counts and each of the four molecular markers using the CXC CellSearch® kit.
Results: 21 pts have been accrued to the feasibility study. One patient was ineligible. Five of 20 pts had low CTC counts (<5 CTC/7.5ml whole blood), and are expected to have a relatively favorable prognosis. CTC-ETI was successfully determined in 10 pts (50%): 2 pts had low, while 3 had intermediate, and 5 had high CTC-ETI. Technical difficulties precluded accurate CTC-ETI in the remaining 5 patients. Of note, expression of the biomarkers among CTC in single patients was heterogeneous, suggesting that future iterations of the CTC-ETI will have to consider expression variability. Further exploratory results regarding associations between CTC-ETI and outcomes will be presented.
Conclusions: ER, BCL-2, HER-2, and Ki-67 can be accurately determined on CTC using the 4th channel in the CellSearch® system to calculate CTC-ETI. We predict that lower CTC-ETI scores (low or no CTC, or CTC with high CTC ER and BCL-2 and low CTC HER-2 and Ki-67) could be associated with favorable response to ET. Successful completion of the feasibility study will lead to a prospective trial to determine if high CTC-ETI at baseline predicts resistance and rapid progression on ET in women starting a new endocrine therapy for MBC.
Supported by Veridex, LLC, Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale ™ (DFH), Associazione Sandro Pitigliani and by a studentship from FIRC (CP).
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-07-16.
Collapse
Affiliation(s)
- C Paoletti
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - MC Connelly
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - DA Chianese
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - ME Brown
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - MC Muñiz
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - JM Rae
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - DG Thomas
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - DF Hayes
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| |
Collapse
|
33
|
Abstract
Abstract
A range of factors was established, such as knowledge and ethics, which underlay the practice of six groups of health professionals: pharmacists, dentists, doctors, nurses, optometrists and radiographers. These factors have been identified as “concepts”. The method used was content analysis of official documents of the professions, such as codes of ethics and guidance documents. Postal questionnaires were also used to collect data. Nine principal concepts were identified. A “collective professional consciousness” was evident, in which knowledge, patient welfare and ethics were important concepts for the highest quality of practice. The perceived importance of these and other concepts was broadly similar across the professions.
Collapse
Affiliation(s)
- M E Brown
- Great Yarmouth and Waveney health authority
| | - S Ellis
- East Anglian regional health authority
| | - P A Linley
- Pharmacy Practice Research Unit, University of Bradford
| | - T G Booth
- Pharmacy Practice Research Unit, University of Bradford
| |
Collapse
|
34
|
Brown ME, Ellis S, Linley PA, Booth TG. Professional values and pharmacy practice: implications of a predominantly female Register of Pharmaceutical Chemists. International Journal of Pharmacy Practice 2011. [DOI: 10.1111/j.2042-7174.1992.tb00563.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Abstract
It is expected that the Register of Pharmaceutical Chemists of Great Britain will comprise a majority of female practitioners by about the year 2000. It is, therefore, pertinent to compare the opinions of male and female practitioners (pharmacists, doctors, dentists, nurses, optometrists and radiographers) about their practice. This study uses methodology published in an earlier paper to identify those opinions. Male and female practitioners had similar views in three areas: the concepts they considered important for the highest quality of practice, their valuation of patient safety, and the prevalence of conflict between National Health Service policies and professional ideas. There were three concepts which female practitioners considered more important than did males. One was confidentiality. Another was law (and, indeed, more male, than female, pharmacists were both investigated by the Royal Pharmaceutical Society's Statutory Committee and removed from the Register). The third was “health care art”: a new balance between the artistic and scientific sides of pharmacy is predicted when the majority of pharmacists are female. The one concept which male practitioners considered more important was independence. This may be related to the lower proportion of females than males who have risen to positions of authority.
Collapse
Affiliation(s)
- M E Brown
- Great Yarmouth and Waveney health authority
| | - S Ellis
- East Anglian regional health authority
| | - P A Linley
- School of Pharmacy, University of Bradford
| | - T G Booth
- Pharmacy Practice Research Unit, University of Bradford
| |
Collapse
|
35
|
Pendergrass KD, Varghese ST, Maiellaro-Rafferty K, Brown ME, Taylor WR, Davis ME. Temporal effects of catalase overexpression on healing after myocardial infarction. Circ Heart Fail 2010; 4:98-106. [PMID: 20971939 DOI: 10.1161/circheartfailure.110.957712] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND Reactive oxygen species, such as hydrogen peroxide (H(2)O(2)), contribute to progression of dysfunction after myocardial infarction (MI). However, chronic overexpression studies do not agree with acute protein delivery studies. The purpose of the present study was to assess the temporal role of cardiomyocyte-derived H(2)O(2) scavenging on cardiac function after infarction using an inducible system. METHODS AND RESULTS We developed a tamoxifen-inducible, cardiomyocyte-specific, catalase-overexpressing mouse. Catalase overexpression was induced either 5 days before or after MI. Mice exhibited a 3-fold increase in cardiac catalase activity that was associated with a significant decrease in H(2)O(2) levels at both 7 and 21 days. However, cardiac function improved only at the later time point. Proinflammatory and fibrotic genes were acutely upregulated after MI, but catalase overexpression abolished the increase despite no acute change in function. This led to reduced overall scar formation, with lower levels of Collagen 1A and increased contractile Collagen 3A expression at 21 days. CONCLUSIONS In contrast to prior studies, there were no acute functional improvements with physiological catalase overexpression before MI. Scavenging of H(2)O(2), however, reduced proinflammatory cytokines and altered cardiac collagen isoforms, associated with an improvement in cardiac function after 21 days. Our results suggest that sustained H(2)O(2) levels rather than acute levels immediately after MI may be critical in directing remodeling and cardiac function at later time points.
Collapse
Affiliation(s)
- Karl D Pendergrass
- Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, 101 Woodruff Circle, Atlanta, GA 30322, USA
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
Of the many types of biomolecules used for molecular imprinting applications, proteins are some of the most useful, yet challenging, templates to work with. One method, termed the 'epitope approach', involves imprinting a short peptide fragment of the protein into the polymer to promote specific adsorption of the entire protein, similar to the way an antigen binds to an antibody via the epitope. Whole lysozyme or the 16 residue lysozyme C peptide was imprinted into porous silica scaffolds using sol-gel processing. After removing template, scaffolds were exposed to lysozyme and/or RNase A, which was used as a competitor molecule of comparable size. When comparing protein- to peptide-imprinted scaffolds, similar amounts of lysozyme and RNase were bound from single protein solutions. However, while whole lysozyme-imprinted scaffolds showed about 4:1 preferential binding of lysozyme to RNase, peptide-imprinted scaffolds failed to show statistical significance, even though a slight preferential binding trend was present. These initial studies suggest there is potential for using peptide-imprinting to create specific protein-binding sites on porous inorganic surfaces, although further development of the materials is needed.
Collapse
Affiliation(s)
- M E Brown
- Center for Biomedical Engineering, University of Kentucky, Lexington, KY 40506
| | | |
Collapse
|
37
|
West RA, Brown ME, Salinas SV, Bouchez AH, Roe HG. No oceans on Titan from the absence of a near-infrared specular reflection. Nature 2005; 436:670-2. [PMID: 16079839 DOI: 10.1038/nature03824] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2005] [Accepted: 05/18/2005] [Indexed: 11/08/2022]
Abstract
With its substantial atmosphere of nitrogen, hydrocarbons and nitriles, Saturn's moon Titan is a unique planetary satellite. Photochemical processing of the gaseous constituents produces an extended haze that obscures the surface. Soon after the Voyager fly-bys in 1980 and 1981 photochemical models led to the conclusion that there should be enough liquid methane/ethane/nitrogen to cover the surface to a depth of several hundred metres. Recent Earth-based radar echoes imply that surface liquid may be present at a significant fraction of the locations sampled. Here we present ground-based observations (at near-infrared wavelengths) and calculations showing that there is no evidence thus far for surface liquid. Combined with the specular signatures from radar observations, we infer mechanisms that produce very flat solid surfaces, involving a substance that was liquid in the past but is not in liquid form at the locations we studied.
Collapse
Affiliation(s)
- R A West
- MS 169-237 Jet Propulsion Laboratory, 4800 Oak Grove Drive, Pasadena, California 91109, USA.
| | | | | | | | | |
Collapse
|
38
|
Abstract
The orbital parameters of a satellite revolving around 22 Kalliope indicate that the bulk density of this main-belt asteroid is 2.37 +/- 0.4 grams per cubic centimeter. M-type asteroids such as Kalliope are thought to be the disrupted metallic cores of differentiated bodies. The low-density indicates that Kalliope cannot be predominantly composed of metal and may be composed of chondritic material with approximately 30% porosity. The satellite orbit is circular, suggesting that Kalliope and its satellite have different internal structures and tidal dissipation rates. The satellite may be an aggregate of impact ejecta from an earlier collision with Kalliope.
Collapse
Affiliation(s)
- J L Margot
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA.
| | | |
Collapse
|
39
|
McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MHL, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HTJ, Przybylski M, St George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002; 8:1263-9. [PMID: 12379850 DOI: 10.1038/nm790] [Citation(s) in RCA: 328] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2002] [Accepted: 10/01/2002] [Indexed: 11/09/2022]
Abstract
Immunization of transgenic mouse models of Alzheimer disease using amyloid-beta peptide (Abeta) reduces both the Alzheimer disease-like neuropathology and the spatial memory impairments of these mice. However, a therapeutic trial of immunization with Abeta42 in humans was discontinued because a few patients developed significant meningo-encephalitic cellular inflammatory reactions. Here we show that beneficial effects in mice arise from antibodies selectively directed against residues 4-10 of Abeta42, and that these antibodies inhibit both Abeta fibrillogenesis and cytotoxicity without eliciting an inflammatory response. These findings provide the basis for improved immunization antigens as well as attempts to design small-molecule mimics as alternative therapies.
Collapse
Affiliation(s)
- J McLaurin
- Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Harty RN, Brown ME, McGettigan JP, Wang G, Jayakar HR, Huibregtse JM, Whitt MA, Schnell MJ. Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J Virol 2001; 75:10623-9. [PMID: 11602704 PMCID: PMC114644 DOI: 10.1128/jvi.75.22.10623-10629.2001] [Citation(s) in RCA: 169] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2001] [Accepted: 08/08/2001] [Indexed: 11/20/2022] Open
Abstract
The matrix (M) proteins of vesicular stomatitis virus (VSV) and rabies virus (RV) play a key role in both assembly and budding of progeny virions. A PPPY motif (PY motif or late-budding domain) is conserved in the M proteins of VSV and RV. These PY motifs are important for virus budding and for mediating interactions with specific cellular proteins containing WW domains. The PY motif and flanking sequences of the M protein of VSV were used as bait to screen a mouse embryo cDNA library for cellular interactors. The mouse Nedd4 protein, a membrane-localized ubiquitin ligase containing multiple WW domains, was identified from this screen. Ubiquitin ligase Rsp5, the yeast homolog of Nedd4, was able to interact both physically and functionally with full-length VSV M protein in a PY-dependent manner. Indeed, the VSV M protein was multiubiquitinated by Rsp5 in an in vitro ubiquitination assay. To demonstrate further that ubiquitin may be involved in the budding process of rhabdoviruses, proteasome inhibitors (e.g., MG132) were used to decrease the level of free ubiquitin in VSV- and RV-infected cells. Viral titers measured from MG132-treated cells were reproducibly 10- to 20-fold lower than those measured from untreated control cells, suggesting that free ubiquitin is important for efficient virus budding. Last, release of a VSV PY mutant was not inhibited in the presence of MG132, signifying that the functional L domain of VSV is required for the inhibitory effect exhibited by MG132. These data suggest that the cellular ubiquitin-proteasome machinery is involved in the budding process of VSV and RV.
Collapse
Affiliation(s)
- R N Harty
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, 19104, USA.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Harty RN, Brown ME, Hayes FP, Wright NT, Schnell MJ. Vaccinia virus-free recovery of vesicular stomatitis virus. J Mol Microbiol Biotechnol 2001; 3:513-7. [PMID: 11545270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
The advent of reverse-genetics represents a powerful new approach to elucidate aspects of negative-sense RNA virus replication. The reverse-genetics system established previously for vesicular stomatitis virus (VSV) required four plasmids encoding the nucleoprotein (N), phosphoprotein (P), polymerase (L), and the full-length, anti-genomic RNA. Transcription to yield the antigenomic RNA as well as the N, P, and L, mRNAs was initiated by bacteriophage T7 polymerase expressed from a recombinant Vaccinia virus. In this report, we describe the successful recovery of infectious VSV in the absence of Vaccinia virus. The N, P, and L genes of VSV were inserted downstream of both the T7 promoter and an internal ribosomal entry site (IRES element). T7 polymerase was expressed constitutively from BSR-T7/5 cells. RTPCR was used to confirm that the recovered VSV was derived from transfected DNA. Virion protein profile, CPE in tissue culture, and virus titer of the recombinant VSV were indistinguishable from those of parental VSV. Thus, the need for Vaccinia virus is eliminated with this system, making it an attractive, alternative approach for the recovery of infectious VSV from DNA.
Collapse
Affiliation(s)
- R N Harty
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia 19104-6049, USA.
| | | | | | | | | |
Collapse
|
42
|
Pisano ED, Britt GG, Lin Y, Schell MJ, Burns CB, Brown ME. Factors affecting phantom scores at annual mammography facility inspections by the U.S. Food and Drug Administration. Acad Radiol 2001; 8:864-70. [PMID: 11724041 DOI: 10.1016/s1076-6332(03)80765-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
RATIONALE AND OBJECTIVES The authors performed this study to evaluate the factors affecting phantom image score at the annual inspection of mammography facilities. MATERIALS AND METHODS In 1997, three U.S. Food and Drug Administration (FDA)-trained inspectors performed inspections of all mammography facilities in North Carolina. All federal and state inspection data were collected and evaluated by using linear regression analysis. Factors affecting the American College of Radiology phantom scores were assessed. RESULTS Phantom score was affected by inspector identity, view box luminance, and optical density. All of these factors had a statistically significant effect on mass score (P < .05). Inspector identity yielded a statistically significant effect on speck group score, fibril score, and total score. Luminance yielded a statistically significant effect on both speck group score and total score. CONCLUSION Phantom scoring should be automated to allow for more consistent interobserver scoring. In addition, radiology facilities can improve the likelihood of receiving a passing phantom score by reducing the ambient light and increasing the view box luminance in the location where the images are evaluated and the phantom is scored routinely. Radiologists should also consider increasing phantom and clinical image optical density to allow for improved phantom testing outcomes.
Collapse
Affiliation(s)
- E D Pisano
- Department of Radiology, and the UNC-Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill 27599-7510, USA
| | | | | | | | | | | |
Collapse
|
43
|
Abstract
Chemical risk assessments often focus on measuring exposure as if individuals were subject only to exogenous environmental sources of risk. For infectious diseases, exposure might not only depend on exogenous sources of microbes, but also on the infection status of other individuals in the population. For example, waterborne infections from agents such as Cryptosporidium parvum and Escherichia coli: O157:H7 might be transmitted from contaminated water to humans through drinking water; from interpersonal contact; or from infected individuals to the environment, and back to other susceptible individuals. These multiple pathways and the dependency of exposure on the prevalence of infection in a population suggest that epidemiological models are required to complement standard risk assessments in order to quantify the risk of infection. This paper presents new models of infection transmission systems that are being developed for the US Environmental Protection Agency as part of a project to quantify the risk of microbial infection. The models are designed to help inform water treatment system design decisions.
Collapse
Affiliation(s)
- S E Chick
- Department of Industrial and Operations Engineering, The University of Michigan, Ann Arbor 48109-2117, USA.
| | | | | | | |
Collapse
|
44
|
Abstract
Several lines of evidence suggest that cannabis may have antidepressant effects. However, methodologic limitations in available studies make the results difficult to interpret. We review this literature and present five cases in which the evidence seems particularly clear that marijuana produced a direct antidepressant effect. If true, these observations argue that many patients may use marijuana to "self-treat" depressive symptoms.
Collapse
Affiliation(s)
- A J Gruber
- Biological Psychiatry Laboratory, McLean Hospital, Belmont, Massachusetts 02178, USA
| | | | | |
Collapse
|
45
|
Abstract
Physicians provide one source of information about the quality of care in health plans, but concerns exist that physicians cannot distinguish quality from financial considerations or other underlying attitudes. We examined whether physicians can (a) distinguish different domains of health plan quality and (b) distinguish health plan quality from their underlying attitudes. We analyzed data on 419 generalist physicians from four health plans. Three scales assessed physicians' perceptions of facilitators and barriers to high-quality care in the plans and the clinical capabilities of plan physicians. Structural equation modeling indicated that physicians could distinguish domains of health plan quality. Physicians could also distinguish plan quality from their attitudes toward the plan, but plan quality was more highly correlated with general managed care attitudes than expected. These data suggest that physicians can provide information about health plan quality, but it will be important to validate these measures against patient outcomes.
Collapse
Affiliation(s)
- M A Smith
- University of Wisconsin-Madison Medical School, USA
| | | | | | | | | | | |
Collapse
|
46
|
Affiliation(s)
- M E Brown
- Southern Illinois University School of Law, USA
| |
Collapse
|
47
|
Abstract
Avascular necrosis of bone (osteonecrosis) that is atraumatic is most frequently associated with corticosteroid excess or alcoholism and usually involves the femoral head. We report a case of multifocal avascular necrosis in a 38-year-old woman with autoimmune Addison's disease taking corticosteroid replacement therapy. The onset of joint symptoms occurred 6 months after a pregnancy complicated by acute fatty liver and disseminated intravascular coagulation. Although both knees and ankles were involved, an unusual feature is that the hips were spared. As illustrated in this patient, avascular necrosis is frequently misdiagnosed in cases of joint pain of acute onset and may occur in the context of physiologic replacement doses of corticosteroids. Etiologic factors can precede the onset of symptoms and the diagnosis by several months.
Collapse
Affiliation(s)
- M E Brown
- Department of Rheumatology, Derriford Hospital, Plymouth, United Kingdom
| | | | | |
Collapse
|
48
|
Reichler SA, Balk J, Brown ME, Woodruff K, Clark GB, Roux SJ. Light differentially regulates cell division and the mRNA abundance of pea nucleolin during de-etiolation. Plant Physiol 2001; 125:339-50. [PMID: 11154341 PMCID: PMC61014 DOI: 10.1104/pp.125.1.339] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/12/2000] [Revised: 03/23/2000] [Accepted: 08/03/2000] [Indexed: 05/19/2023]
Abstract
The abundance of plant nucleolin mRNA is regulated during de-etiolation by phytochrome. A close correlation between the mRNA abundance of nucleolin and mitosis has also been previously reported. These results raised the question of whether the effects of light on nucleolin mRNA expression were a consequence of light effects on mitosis. To test this we compared the kinetics of light-mediated increases in cell proliferation with that of light-mediated changes in the abundance of nucleolin mRNA using plumules of dark-grown pea (Pisum sativum) seedlings. These experiments show that S-phase increases 9 h after a red light pulse, followed by M-phase increases in the plumule leaves at 12 h post-irradiation, a time course consistent with separately measured kinetics of red light-induced increases in the expression of cell cycle-regulated genes. These increases in cell cycle-regulated genes are photoreversible, implying that the light-induced increases in cell proliferation are, like nucleolin mRNA expression, regulated via phytochrome. Red light stimulates increases in the mRNA for nucleolin at 6 h post-irradiation, prior to any cell proliferation changes and concurrent with the reported timing of phytochrome-mediated increases of rRNA abundance. After a green light pulse, nucleolin mRNA levels increase without increasing S-phase or M-phase. Studies in animals and yeast indicate that nucleolin plays a significant role in ribosome biosynthesis. Consistent with this function, pea nucleolin can rescue nucleolin deletion mutants of yeast that are defective in rRNA synthesis. Our data show that during de-etiolation, the increased expression of nucleolin mRNA is more directly regulated by light than by mitosis.
Collapse
Affiliation(s)
- S A Reichler
- Section of Molecular Cell and Developmental Biology, University of Texas, Austin, Texas 78713, USA
| | | | | | | | | | | |
Collapse
|
49
|
Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci U S A 2000; 97:13871-6. [PMID: 11095724 PMCID: PMC17668 DOI: 10.1073/pnas.250277297] [Citation(s) in RCA: 374] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
VP40, the putative matrix protein of both Ebola and Marburg viruses, possesses a conserved proline-rich motif (PY motif) at its N terminus. We demonstrate that the VP40 protein can mediate its own release from mammalian cells, and that the PY motif is important for this self-exocytosis (budding) function. In addition, we used Western-ligand blotting to demonstrate that the PY motif of VP40 can mediate interactions with specific cellular proteins that have type I WW-domains, including the mammalian ubiquitin ligase, Nedd4. Single point mutations that disrupted the PY motif of VP40 abolished the PY/WW-domain interactions. Significantly, the full-length VP40 protein was shown to interact both physically and functionally with full-length Rsp5, a ubiquitin ligase of yeast and homolog of Nedd4. The VP40 protein was multiubiquitinated by Rsp5 in a PY-dependent manner in an in vitro ubiquitination assay. These data demonstrate that the VP40 protein of Ebola virus possesses a PY motif that is functionally similar to those described previously for Gag and M proteins of specific retroviruses and rhabdoviruses, respectively. Last, these studies imply that VP40 likely plays an important role in filovirus budding, and that budding of retroviruses, rhabdoviruses, and filoviruses may proceed via analogous mechanisms.
Collapse
Affiliation(s)
- R N Harty
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce Street, Philadelphia, PA 19104-6049, USA.
| | | | | | | | | |
Collapse
|
50
|
|